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ABSTRACT 
Over the past fifty years anthracyclines have been used to treat a wide variety of 
cancers.  Combination therapies with anthracyclines have the potential to greatly increase 
treatment success.  Despite the great potential of anthracyclines in the treatment of 
cancer, their use has been limited due to the risk of chronic cardiotoxicity.  The reduction 
of anthracyclines to an alcohol metabolite has been linked to the development of  
cardiotoxic side effects.  One of the principal enzymes responsible for catalyzing the 
formation of the anthracycline alcohol metabolite is human carbonyl reductase 1 
(HCBR).  Controlling the reduction of anthracyclines by HCBR may offer a means to 
reduce the risk of cardiotoxicity during treatment.   
The structure activity relationships responsible for the recognition and binding of 
the anthracycline substrates were investigated.  Molecular modeling studies implicated 
Met 234 as a possible determinant of anthracycline specificity for HCBR.  In order to test 
this, site directed mutagenesis was used to convert the methionine to a cysteine in a 
histidine expression system.  The histidine tagged HCBR was found to have reduced 
enzyme activity and coenzyme binding compared to native enzyme.  Further, the cysteine 
234 mutant enzyme was found to be inactive, although it still appeared to possess 
coenzyme and anthracycline binding capability.   It is clear that the addition of the 
histidine tag has impaired enzyme function and that such a modification may mask any 
effects introduced by mutating Met 234 to a cysteine (NIH-INBRE Grant # 
P20RR16454).
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CHAPTER 1 
CANCER THERAPIES: ANTHRACYCLINE TREATMENTS AND POTENTIAL  
 
HEALTH RISKS 
 
Anthracyclines in the Treatment of Cancer 
 
History of Anthracycline Therapies 
 
Anthracyclines are antibiotics that are effective treatments for a variety of 
aggressive cancers.1  Among cancer treatment drugs, anthracyclines have activity on the 
widest range of cancers.1 Doxorubicin has been considered the most potent neoplastic 
agent in the anthracycline class of drugs and has the widest spectrum of use. 2  Only a 
few types of cancers are unresponsive to anthracycline therapy. 2   
Daunorubicin and doxorubicin are two types of anthracyclines that were first 
isolated from the Streptomyces peucetius bacteria in the early 1960’s and are still widely 
used.  These two drugs are good models for cancer research because the structures of 
these drugs differ by only one hydroxyl group; however, they differ in cytotoxic behavior 
(Figure 1.1).1  
Doxorubicin is used in the treatment of solid tumors and includes breast, lung, 
thyroid, ovary carcinomas, childhood solid tumors, soft tissue sarcomas, cancers of the 
blood and aggressive lymphomas.  Daunorubicin is used to treat acute leukemias such as 
lymphoblastic and myeloblastic leukemias.1-3  Over 2000 analogs of daunorubicin have 
been made and the data show that small structural changes induce large changes in 
chemical behavior. 2     
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Figure 1.1: Structure of Daunorubicin and Doxorubicin 
 
A) Daunorubicin, B) Doxorubicin 
These two anthracyclines have very similar structures; however, they differ greatly in behavior (Table 1.1).  
The only difference in structure between daunorubicin and doxorubicin is the addition of one hydroxyl 
group on C-14. 
 
Even though anthracyclines have been shown to be very effective in the killing of 
cancer cells the clinical use of anthracyclines is limited by significant side effects for 
some patients.  In 1967 it was discovered that daunorubicin could induce fatal 
cardiotoxicity. 2  Other analogs have been made that aim to either increase the 
cytotoxicity or decrease cardiotoxicity of this treatment; however, the cardiotoxicity of 
these treatments remain high.  The clinical use of daunorubicin and doxorubicin covers 
over fifty years and an analog that is a potent cancer cell killer and has diminished 
cardiotoxicity properties has yet to be made.     
Cytotoxic Mechanisms of Anthracyclines 
The cytotoxicity mechanisms are not well understood for anthracyclines.  
Anthracyclines are passively transported through the membrane in an uncharged form.4 
pH gradients along the membrane influence the accumulation of daunorubicin in cells.4  
Anthracyclines are targeted to the nucleus of the cell where it causes cell damage at the 
DNA level.5  Cytotoxic mechanisms are thought to involve DNA intercalation, 
interruption of the topoisomerase II enzyme and free radical production.1,6,7   
 
  3 
Intercalation into DNA Strands 
Intercalation involves the drug inserting directly into the DNA molecule and is 
essential for drug activity.  Doxorubicin and daunorubicin intercalate with B-DNA and 
show little affinity for A-DNA, left-handed Z-DNA and RNA duplexes.3  The 
intercalation is DNA sequence specific where daunorubicin prefers to intercalate at 
alternating pyrimidine-purine stretches.8  The anthraquinone intercalates between two 
base pairs of DNA and prefers to bind at CPG islands.3 
The amino sugar also intercalates into the DNA but the pattern of intercalation is 
variable between the different drugs.  The amino group determines the specific DNA 
sequence to which the drug will bind.9  In both daunorubicin and doxorubicin, the amino 
sugar of both drugs extends into the minor groove of DNA but the conformation of the 
anthracycline molecule can vary depending on the surrounding DNA sequence.  
Daunorubicin’s amino sugar has direct hydrogen bonding to the DNA while other 
anthracyclines make van der Waals contact with base pairs.  The hydrogen bond acceptor 
varies for those drugs that have hydrogen bond contacts with the amino sugar and DNA.8 
 Recent studies have also focused on the role that formaldehyde may play in the 
formation of DNA-adducts by anthracyclines.  Studies have found that the presence of 
formaldehyde aided the adduct formation when anthracyclines were present.  It was 
found that formaldehyde joins two anthracycline drugs together by a bridge at the 3’ 
amino group of the sugar group (Figure 1.2).10  The resulting molecule is called 
doxoform.  Doxoform then interacts with the DNA causing DNA-adducts (Figure 1.3).5   
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 Figure 1.2: Formaldehyde Conjugated with Doxorubicin 
 
 
Formaldehyde has been found to interact with anthracycline molecules.  Here formaldehyde binds the 3’ 
amino group of the anthracycline sugar joining two anthracycline molecules together.  Doxoform(R=OH), 
Daunoform (R=H).  5 
 
Figure 1.3: Formaldehyde Aids Doxorubicin Adduct Formation 
 
Structure of the formaldehyde-mediated doxorubicin adduct to DNA molecules.  The presence of 
formaldehyde may increase the ability for doxorubicin to intercalate into DNA and cause cellular damage 
to cancer cells.  5   
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Cancer cells have been found to form formaldehyde.  The metabolism of 
anthracyclines as well as the oxidative stress induced by treatment can lead to 
formaldehyde formation in the cell as well.11  The presence of formaldehyde may 
increase the DNA-adduct formation and lead to increased cancer cell death. 
 The insertion changes the structure of DNA and inhibits the replication of cancer 
cells by blocking the synthesis of macromolecules and mRNA transcription.  It is 
believed that intercalation interferes with DNA polymerases, DNA methyltransferases 
(DNMT1), DNA ligases and helicases.  DNA repair enzymes are also inhibited from 
binding the anthracycline intercalated DNA and inhibits repair to damaged DNA.12 This 
interruption of the DNA repair enzymes ability to function is also crucial to the 
interruption of the topoisomerase II enzyme discussed below. All of these effects can lead 
to cancer cell death by activating apoptotic response systems. 
 Interruption of the Topoisomerase II Enzyme 
 Anthracyclines are well known topoisomerase II poisons and this property is 
believed to play a significant role in the mechanism of anthracycline cytotoxicity.1  The 
role of topoisomerase II enzymes in the cell is to regulate the topology of DNA during 
DNA replication and transcription activities.13  Topoisomerase II can catalyze several 
reactions that include knotting and unknotting DNA, catenation and decatenation of sister 
chromosomes and relaxation of super helical twists.14  The role of topoisomerase II is 
essential for cell viability.  Without this enzyme cells face the potential of not being able 
to separate chromosomes for replication, fail to transcribe genetic information, lack the 
ability to manage the topology of DNA regions and would fail to replicate.13   
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 One role of Topoisomerase II in the cell is to relieve stress that is produced at the 
replication fork during DNA replication.  During the cytotoxic response of anthracyclines 
this characteristic is exploited.  In the normal cell cycle, during DNA replication, DNA 
helicases unwind segments of DNA for gene transcription and this process introduces 
topological stress on the DNA strands.  Topoisomerase II makes transient double 
stranded nicks in the DNA strand ahead of the replication fork during DNA synthesis to 
relieve this stress (Figure 1.4).15   
Figure 1.4: Regulation of Topoisomerase II by Anthracycline Drugs 
 
 
Topoisomerase II relieves stress that builds up on a DNA strand during DNA replication.  This 
enzyme regulates the topology of DNA by cutting a double stranded DNA segment and passing another 
double strand segment through the region.  The cut region is re-ligated by topoisomerase II.  In this figure 
the double stranded DNA segment labeled G will undergo cutting.  The double stranded segment labeled T 
will be passed through the G segment.   
In stage 1 the two subunits of topoisomerase II come together.  In step 2 the double stranded DNA 
is covalently bound to the enzyme and segment G is cut.  In step three the T segment of DNA is passed 
through the DNA.  And in step four the G segment of DNA is re-ligated.  This is a reversible reaction that 
requires the input of ATP.16   
Anthracyclines are able to prevent the re-ligation of the strands by stabilizing form 3 of 
topoisomerase II.  The topoisomerase enzyme is transformed into a DNA damaging enzyme.16 
 
The catalytic reaction of topoisomerase II occurs in discrete steps.  To initiate this 
reaction the enzyme forms a covalent bond between the tyrosine residues and the DNA 
sugar-phosphate backbone of a double stranded region of DNA – which has been referred 
to as the gate region.  This is followed by topoisomerase II cutting the double stranded 
DNA at the gate region, and then passing another double stranded DNA region through 
the cut gate.   After the duplex region has been passed through the cut DNA the covalent 
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bond is reversed leading to the re-ligation of the DNA strands and the release of the 
bound DNA gate region.  The enzyme undergoes a conformational change so that it is 
ready to start the reaction over again with another region of DNA.16  
 Anthracyclines are able to stabilize the enzyme-DNA covalent adduct, thus 
preventing the re-ligation of the DNA strands.  The anthracyclines bind the enzyme’s 
active site and when the DNA strands are cut, the DNA is irreversibly, covalently bound 
to the catalytic tyrosine residues in the enzyme (Figure 1.4).  In the presence of 
anthracyclines these topoisomerase II-DNA complexes increase in number.  The result is 
that topoisomerase II is transformed into a DNA damaging agent and the DNA molecules 
of the cell undergo fragmentation at many different sites.17 Such DNA damage can 
overwhelm the cell and will cause growth arrest in the G1 and G2 phase and ultimately 
the cell will undergo apoptosis.1    
 Topoisomerase II poisons affect the viability of both normal cells and cancer 
cells; however, the response is more pronounced in the cancer cell.  There are several key 
characteristics that distinguish cancer cell phenotypes from normal cells.  Proliferation 
states between these two types of cells can be substantially different.  Cancer cells often 
proliferate at an increased rate than normal cells leading to an increase in the proteins that 
are needed for cell replication.18  Due to the importance of topoisomerase II in the cell 
replication cycle13 this enzyme can be up-regulated in the cancer cell.  Anthracycline 
cytotoxicity is hypothesized to rely on the increased topoisomerase II targets to induce 
the cancer cell deaths.  
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Oxidative Damage and Free Electron Radical Formation 
Reactive oxygen species generated by anthracycline re-dox cycling have also 
been implicated in the cytotoxic mechanism of anthracyclines (Figure 1.5).1,6,7,19,20   
Figure 1.5: Reactive Oxygen Generation by Doxorubicin.   
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Single electron reduction/oxidation cycling between the doxorubicin quinone (A) and the semiquinone (B) 
radical.  This is a cyclic reaction that regenerates the parent compound and generates oxygen free radicals.  
The reaction can be catalyzed by many enzymes in the body. 
 
There is evidence that as doxorubicin is added to heart tissue in vitro superoxide 
formation is increased.6  Other drugs that contained a quinone group, like daunorubicin, 
were also tested and found that they significantly increased oxygen free radicals.  In 
addition, drugs that lack a quinone group, such as 5-iminodaunorubicin, did not 
significantly increase oxygen free radicals.  This data implies that in the body the quinone 
group is undergoing a re-dox reaction mediated by the enzyme NADH dehydrogenase.6   
The role of reactive oxygen species in anthracycline cytotoxic mechanisms is still 
a matter of debate.1  Single electron re-dox cycling in anthracyclines has been 
demonstrated using several different NADPH-dependent oxido-reductase enzymes found 
in the body.6,7,19,20 The quinone structure acts as an electron acceptor.  This forms a 
semiquinone species that is highly reactive.  In the presence of molecular oxygen the 
semiquinone reacts to generate radical oxygen species and the parent quinone structure is 
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regenerated.  The parent quinone is now available to undergo another reaction in a cyclic 
manner.  The radical oxygen species that are generated can be superoxide anions or 
hydrogen peroxide.  Both of these species can be damaging to cells and are potentially 
harmful to tissues.1  
This re-dox cycling that occurs with the quinone has been associated with the 
release of intracellular stores of iron.  Anthracycline drugs bind to the free iron to form an 
iron/drug complex (Figure 1.6).  This complex can be very damaging to cells by 
converting the superoxide anions and hydrogen peroxide species generated by the one 
electron cycling events into a hydroxyl radical.  A hydroxyl radical is a highly reactive 
species that is more damaging than reactive oxygen species.1  
Figure 1.6: Anthracyclines/Iron Complex 
 
 
Doxorubicin can form complexes with iron in cells.  The interaction can lead to the formation of hydroxyl 
radicals and may be a potential cytotoxic mechanism. 21 
 
 Damage to lipid membranes may also occur due to these oxidative reactions.  The 
aglycone portion of the anthracyclines has increased lipid solubility and tends to 
intercalate into the lipid membrane of the cell.  The quinone portions of the drug can still 
  10 
undergo oxidation reactions creating reactive oxygen species near the membrane of the 
cells.  Lipid peroxidation can result and damage cancer cells.1 
 It is still being debated whether these free radical and oxidative reactions occur 
appreciably at clinically relevant concentrations of anthracyclines. Several investigators 
have made the point that the effects seen as a result of generating reactive oxygen species 
are observed at anthracycline concentrations that are higher than would be achieved 
during treatment in a clinical setting.  Further, these free radical species have been 
implicated in the mechanism of cardiotoxicity often associated with anthracycline 
treatments and any cytotoxic benefit may be outweighed by the cardiotoxic effects.    
Potential Side Effects of Anthracycline Therapies 
Acute Side Effects of Anthracycline Treatment 
 Patients undergoing an anthracycline treatment regime may or may not suffer side 
effects from their treatment.  Some side effects are an acute response that manifest within 
hours or days of beginning treatment while other side effects may occur years after 
treatment.22  The most severe side effect is cardiotoxicity that can manifest itself in an 
acute or chronic manner and has the potential to manifest twenty years after treatment.22  
 A study conducted by Griffin et.al. asked cancer patients to identify and rank the 
severity of their chemotherapy side effects.23  They found that patients experienced 
twenty different symptoms, thirteen were physical symptoms and seven were 
psychosocial symptoms. The top five symptoms that were experienced by patients were 
loss of hair, nausea, fatigue, vomiting and increased urination.  The symptoms that 
patients ranked as the most severe were: nausea, tiredness and loss of hair.  These 
researchers also found that the types of symptoms suffered or the severity of the 
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symptoms did vary depending on patient factors such as age, gender, and extent of 
disease.23  
 Nausea, Vomiting and Fatigue Symptoms Impact Patient Health 
Mild or moderate nausea and vomiting are very common with anthracycline based 
treatments; however, some patients suffer severe symptoms.24  These symptoms can be 
controlled clinically with the prescription of anti-nausea drugs.25  Fatigue associated with 
doxorubicin can affect a significant portion of patients.  Studies have found that 99% of 
chemotherapy patients suffer some degree of fatigue during treatment.26  Another study 
reported that two thirds of breast cancer patients reported moderate or severe fatigue 
during treatment.25  This symptom seems to be limited to treatment and tends to 
disappear after treatment is completed;25 however, these symptoms can persist months up 
to years after treatment.26  Fatigue may be due to anemia, treatment induced sleep 
disturbance and depression symptoms.25  
Decrease in White Blood Count and Risk of Infection   
Within fourteen days patients can suffer from myelosuppression which is a drop 
in white blood cell count.  Most female patients undergoing treatment for breast cancer 
will see their white cell count return to normal by their next anthracycline treatment.  Life 
threatening infections that result from the suppressed white blood cell count occurs in 
less than two percent of patients.25  
Ovarian Failure and Menopausal Symptoms 
Doxorubicin treatment may induce ovarian failure which can mimic menopausal 
symptoms and is a common side effect in women.  Patients can be at an increased risk of 
osteoporosis and cardiovascular disease due to this ovarian failure during treatment.  Risk 
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factors include patient age and total dose administered.24  Clinicians can offset 
menopausal symptoms by prescribing intake of calcium and vitamin D, weight bearing 
exercise and monitoring bone density.25  Premature menopausal symptoms can include 
amenorrhea which can be reversible or permanent.  If a patient is still amenorrheic one 
year after treatment they are expected to not regain ovarian function.24 
Weight Gain and Risk for Secondary Disease States 
Several different chemotherapy regimens can cause weight gain.  Doxorubicin 
can cause weight gain in breast cancer patients; however, this symptom is less 
pronounced in doxorubicin treatment than with other chemotherapy treatments.  Weight 
gain is hypothesized to occur due to decreased physical activity, ovarian failure, 
increased food consumption, reduced basal metabolic rate and a decrease in lean body 
mass.  Weight gain may be associated with reoccurring cancer in some patients.25  
Women with breast cancer who gained greater than 5.9 kg of weight during treatment 
were 1.5 times more likely to have a reoccurrence of the cancer and 1.6 times more likely 
to die of breast cancer compared to woman who gained less.27  Premenopausal women 
are at a higher risk for weight gain versus postmenopausal patients.  Patients who 
experience chemotherapy induced menopause are at the highest risk for weight gain.24  
The longer drug administration times may also increase weight gain symptoms.  The 
increase in weight in some patients may further impact their physical health24 possibly 
contributing to diabetes, cardiovascular disease and changes in orthopedics.27     
Chemotherapy-Induced Leukemia 
Some researchers have suggested that chemotherapy regimens such as 
doxorubicin can cause chemotherapy induced acute myeloid leukemia in some patients.25  
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Anthracycline therapies are believed to have a higher incidence of leukemia development 
following treatment as compared to other chemotherapy treatments.  0.1% to 1.5% of 
patients that have undergone standard dose anthracycline therapy are expected to develop 
chemotherapy-associated leukemia;24 however, other researchers suggest that the risk is 
no greater than that for the general population.25  Patients undergoing chemotherapy and 
radiation; however, may be at increased risk for the development of leukemia after 
treatment.25  Doxorubicin-induced leukemia is associated with changes in monocytes and 
a specific cytogenic abnormality that can develop a few years after treatment.  
Doxorubicin induced leukemia does not have to involve myelodysplasia which is 
associated with being a precursor to the development of acute myeloid leukemia.25  
Cardiotoxic Side Effects of Treatment  
Anthracyclines are effective in treating a wide range of cancers; however, clinical 
use is limited by a dose dependent chronic cardiotoxicity.  Some groups of people have a 
higher incidence of complications including younger children (less than four years), older 
patients, females, and patients with a history of hypertension or cardiovascular diseases.  
Cumulative dose and combination therapy have also been implicated in raising the risk of 
cardiotoxicity.28 Analogs have been developed in attempts to reduce the incidence of 
cardiotoxicity and include epirubicin and idarubicin; however, they have not overcome 
the cardiotoxic side effect.  Patients are limited to a lifetime cumulative dose that aims to 
reduce their risk of developing chronic cardiotoxicity.  Patients can suffer acute heart 
problems or chronic heart failure that may manifest several years after completing 
therapy.28   
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It has been proposed that doxorubicin accumulates in the heart tissue followed by 
chronic cardiomyopathy. There is evidence that this problem is correlated to dose, dose 
schedule and patient age.1 Also, different patients respond differently to the anthracycline 
regimens.  Older people suffer different cardiomyopathies than children, females respond 
differently than males, ethnicity puts some races at more risk and Down Syndrome 
patients also face increased cardiomyopathies after treatment.28  
 Physical Manifestations of Cardiotoxicity 
Hallmarks of the cardiotoxic side effects include both acute and chronic heart 
failure and lead to systolic and diastolic dysfunction of the heart tissue.  Cardiotoxic 
damage during anthracycline treatment is believed to involve damage to the myofibrils, 
sarcoplasmic reticulum and mitochondrial damage.29-33   
Early cardiac dysfunction includes changes in the sarcoplasmic reticulae caused 
by vacuole formation.  Sarcoplasmic reticulae are part of the smooth endoplasmic 
reticulum organelles found in eukaryotic cells and they are made up of tubules and 
vesicles.  The job of the sarcoplasmic reticulae is to store calcium ions until heart muscle 
cells are stimulated when they release calcium stores driving the excitation and 
contraction of heart muscle cells (Figure 1.7).34  
Sarcoplasmic reticulum is composed of two parts: longitudinal tubules and 
terminal cisterna (Figure 1.8).  The terminal cisterna is responsible for the storage of 
calcium needed to control relaxation and contraction of muscle fibers.  Doxorubicin has 
been found to inhibit calcium uptake and stimulate calcium release by the terminal 
cisterna.   
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Figure 1.7: Doxorubicin’s Interaction with the Ca++ Channels of Sarcoplasmic 
Reticulum 
 
 
In the cardiotoxic response of anthracyclines, doxorubicin is believed to prevent the uptake of Ca++ into the 
sarcoplasmic reticulum’s terminal cisternia.  Doxorubicin is also believed to promote the release of Ca++ 
previously stored.  This leads to an imbalance in Ca++ in the cell. 21 
 
Figure 1.8: Structure of the Sarcoplasmic Reticulum 
 
 
 
Muscle fibers have a structure called the sarcoplasmic reticulum that helps regulate Ca++ stores in the 
muscle fibers, myofibrils.  They contain two important parts: the longitudinal tubules and terminal 
cisternae.  Doxorubicin is hypothesized to interrupt the Ca++ channels of the terminal cisternae.  Damage 
from treatment can cause the sarcoplasmic reticulae to expand and displace mitochondria and other 
elements from the cell. Image from: (http://www.nvo.com/jin/nss-folder/scrapbook9/m3.gif). 
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The drug was not found to disrupt the function of the longitudinal tubules.35 It is 
believed that hydrogen peroxides, oxidizing agents and free radicals can promote the 
release of calcium in cells.  All of these affects can impair contractility and cardiac 
relaxation.  In later stages of cardiac dysfunction, damaged sarcoplasmic reticulae can 
expand in size and displace contractile elements and mitochondria in the cell.36   
Mitochondria are membrane bound organelles that are considered the power 
houses of cells.  They are responsible for the ATP generation in cells and in very active 
tissues such as heart tissues there can be several hundred mitochondria in one cell.  
Mitochondria also take in calcium ions from the cytosol.  During anthracycline treatment, 
disruption of the mitochondria is observed where the mitochondria swell, are inhibited 
from calcium uptake and formation of calcium inclusions and electron dense bodies are 
observed.37 It has been found that doxorubicin interacts with the electron transport chain 
found in the mitochondria (Figure 1.9).  Doxorubicin can act as a final electron acceptor 
in the reaction mediated by NADH dehydrogenase found at the complex I.  This leads to 
an oxidation reaction involving the quinone group of the anthracycline resulting in 
generation of oxygen free radicals.38  
Figure 1.9: Doxorubicin Interaction with Electron Transport Chain in 
Mitochondria 
 
 
Doxorubicin can act as a final electron acceptor in the electron transport chain at complex 1 in the 
mitochondria.  This reaction can generate free electron radicals that are damaging to the mitochondria and 
to the cell. 39 
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Mitochondria have been well established in the apoptosis response of cells.  One 
mechanism that these organelles use to induce apoptosis is to release cytochrome c 
molecules.  Cytochrome c has been well established to induce a cellular cascade that ends 
with the activation of caspase-3 which induces apoptosis in cells.  It has been found that 
doxorubicin administration can cause the release of cytochrome c from mitochondria, 
leading to activation of caspase-3, followed by cardiomyocyte apoptosis.38 This damage 
to the mitochondria disrupts calcium balance in the cell, disrupts ATP production and is 
believed to induce apoptosis in cardiac cells. 
These early dysfunctions are followed by disorganization and degeneration of 
myofibrils found in the heart muscle tissue.  This damage includes less dense myofibrillar 
bundles, disruption in Z-disc structures and damage to actin filaments.40 Formation of 
vacuoles in the cytoplasm and an increase in the number of lysosomes are also observed.1  
 Combination Therapies Lead to Synergized Cardiotoxic Risk 
Another promising treatment for cancer therapy involves the use of Trastuzumab 
(Herceptin). This drug has been shown to be an especially promising treatment for 
aggressive breast cancers; which is the second leading cause of cancer in women.41 
Clinical trials have shown that this treatment has decreased the recurrence of cancer by 
one half and has decreased mortality by one third in patients.  Trastuzumab treatment 
faces the same failings that anthracycline treatment does: cardiotoxicity.42  
Trastuzumab is a monoclonal antibody that has cytotoxic effects on cells that over 
express the human epidermal growth factor receptor (Her2/Neu) on cell surfaces.  While 
these receptors are over expressed in certain breast cancers they are also expressed in the 
heart.  It is this expression in the heart cell membranes which is the likely cause of the 
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cardiotoxic effects seen in Trastuzumab therapy.  The Trastuzumab cardiotoxicity is 
interesting because the toxicity that is observed is reversible in contrast to anthracycline 
toxicity which is a nonreversible event.41  
One recent advance in chemotherapy treatment has been to combine Trastuzumab 
treatment with anthracycline treatment; however, when these two drugs are used together 
they greatly increase the risk of cardiac dysfunction in patients.41  When Trastuzumab is 
used alone 7% of the patients developed heart failure, when anthracyclines are used alone 
a small percentage of patients developed heart failures; however, when these two drugs 
are used together 28% of the patients developed heart failure.  It is hypothesized that 
when these heart cells undergo another assault, such as one by anthracyclines, the effect 
is synergized.43 This synergy is reflected in the dramatic increase in the percent of 
patients who develop heart failures.  After a combination therapy the cardiotoxicity is 
also nonreversible favoring the toxicity model of anthracyclines.42 Understanding the 
mechanism of cardiotoxicity in anthracycline therapies and being able to address this side 
effect may considerably improve combination therapies, such as this one, leading to 
increased ability to treat aggressive cancers.        
Drug Resistance Side Effects Limit Effectiveness of Anthracycline Treatment 
 P-glycoproteins Transport Anthracyclines Out of the Cell 
Patients undergoing anthracycline therapy may also face drug resistance 
problems.  One possible mechanism includes active drug transport of the anthracyclines 
out of the cell.  One such mechanism includes the multi-drug resistant (MDR) proteins 
found in the membranes of cells.  MDR proteins are responsible for the excretion of a 
large range of drug substrates.  One such MDR protein is p-glycoprotein which transports 
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a wide range of substrates.  Membrane transport proteins like p-glycoproteins contribute 
to drug resistance by decreasing intracellular drug concentrations by an active, ATP-
dependent transport system.44  Several anticancer drugs have been found to be substrates 
of p-glycoprotein, including doxorubicin.45 In mice undergoing treatment with 
anthracyclines, it was found that doxorubicin also up-regulated p-glycoprotein 
expression.46  P-glycoproteins have been shown to be expressed in the heart tissue and 
the expression of these transport proteins varies between individuals.  Multi-drug 
resistant knockout mice, which lack p-glycoproteins, show an accumulation of 
anthracyclines in the heart tissue while mice with a normal complement of p-glycoprotein 
showed a reduction of intracellular levels of anthracyclines.47  
The treatment of cells by an acute dose of doxorubicin has shown a sharp increase 
in the expression of p-glycoproteins located in liver cells.  The doxorubicin treatment 
altered RNA synthesis of the p-glycoproteins as well.  The results of this study indicate 
that exposure to anthracyclines up-regulate the p-glycoproteins and may contribute to 
drug resistance seen in patients.45 
 Non-MDR Protein Pumps Aid Anthracycline Resistance 
 There is significant evidence supporting the active transport of anthracyclines by 
p-glycoproteins; however, there is also evidence that non-MDR proteins also act on the 
removal of anthracyclines from the cell.  One proposed protein is multidrug resistance-
associated protein which is a 190 kD membrane bound glycoprotein.  It also belongs to 
the ABC superfamily of proteins48 although the non-p-glycoprotein transport could 
involve several different protein candidates. 
  20 
 A study completed by Versantvoort investigated the drug resistance of two 
multidrug resistant cell lines that did not express the p-glycoprotein.4  The investigators 
made the cell membranes permeable, administered daunorubicin and then monitored the 
amount of daunorubicin accumulation in the cell to indicate the efflux of the drug.  Cells 
that lacked the p-glycoproteins had a five fold efflux of drug compared to the controls 
that express p-glycoproteins suggesting that other mechanisms of active transport are 
important to daunorubicin efflux.4 
 Multi-drug resistant phenotypes not only efflux anthracycline molecules but also 
may inhibit the cytotoxic response of anthracyclines in cancer cells.  Multi-drug 
resistance phenotypes have protein pumps that are located on the cell membrane.  These 
protein pumps respond to a broad spectrum of drugs that initiate a drug efflux response.18  
Prior to anthracycline treatment, exposure to structurally and functionally unrelated drugs 
can initiate the multi-drug resistance response.  This can result in a faster efflux response 
when the anthracycline treatment is administrated.  The active transport of the 
anthracyclines prevents the accumulation of the drug in the cell.4  The result is that the 
number of anthracyclines molecules that make it to the nucleus are significantly reduced 
preventing the cytotoxic effects on molecular targets.  This decrease of anthracyclines in 
the nucleus may contribute to drug resistance by demanding an increased dosage of drug 
to see the same effects in patients.4    
 Disruption in Intracellular Distribution of Anthracyclines May Lead to Drug 
 Resistance 
 
 Anthracyclines are targeted to the nucleus where there are several cytotoxic 
targets previously discussed.  One mechanism of resistance includes the shifting of 
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anthracycline location in the cell.  When free drug is present in the cell anthracyclines are 
found in the cytoplasm and can be sequestered in acidic vesicles or bound to membranes 
of vesicles.  The cells may be able to compartmentalize the drug in the cell limiting its 
ability to kill cells.48   
 Alterations in Gene Expression of Anthracycline Targets Aid Drug Resistance 
 
 Drug resistance can also occur due to alterations in the gene expression of 
anthracycline specific molecular targets.  One such target is the topoisomerase II enzyme.  
To decrease the cytotoxic effect of anthracyclines cancer cells can down regulate the 
amount of topoisomerase expression in cells, increase the degradation of this enzyme, or 
introduce mutations in the enzyme.48 
 Drug Metabolism May Affect Anthracycline Drug Resistance 
 Another mechanism of drug resistance is due to drug metabolism.  Daunorubicin 
treated tumor cells have an 8-fold increase in the IC50 value for the drug compared to 
cells that were not pretreated with the drug.  This indicated that the treated cells would 
need a larger concentration of drug to achieve the same tumor cell killing results.  These 
treated tumor cells also showed a 6-fold increase in carbonyl reductase activity as 
compared to the non-treated cells.  The carbonyl reductase converts the parent drug 
daunorubicin to daunorubicinol.44 This metabolite is less efficacious in cell killing 
compared to the parent anthracycline.  Therefore, the conversion of daunorubicin to 
daunorubicinol reduces the amount of parent drug in the cell and decreases the overall 
cytotoxicity.   
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Proposed Mechanisms of Cardiotoxicity 
The mechanism of anthracycline cardiotoxicity is not well understood.  Two 
prevailing hypotheses involve metabolite formation and single electron re-dox cycling 
leading to the generation of reactive oxygen species.1 Several mechanisms have been 
proposed that may contribute to the cardiotoxicity and a few of these mechanisms are 
discussed below. 
Reactive Carbonyls 
Current research has focused on the metabolism of the carbonyls found in 
anthracyclines because they have been linked to cardiotoxicity (Figure 1.10).  
Doxorubicin and daunorubicin have two carbonyls that can be reduced by reductases in 
the body: the quinone carbonyls and the C-13 carbonyl.  HCBR 1 is believed to prefer the 
C-13 carbonyl as a substrate compared to the quinone carbonyls.49 
Figure 1.10: Reactive Carbonyls Found in the Anthracyclines 
 
   A. Quinone  B. Carbon 13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
It has been established that there are two reactive carbonyls in the anthracycline molecule.  A)  The quinone 
structure is a carbonyl that can be reduced by different enzymes in the body.  B) Carbon 13 is also a 
carbonyl that can be reduced.  This is an important carbonyl to this research because the reduction of this 
carbonyl by HCBR 1 is linked to the cardiotoxicity observed in patients undergoing anthracycline therapy. 
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 Quinone Structure and the Formation of Reactive Oxygen Species Impact 
 Cardiotoxicity 
 
It is also hypothesized that the quinone structure of anthracyclines undergoes 
metabolism by several different enzymes in the body both cytosolic and in the 
mitochondria.  When the quinone undergoes a single electron reduction, reactive oxygen 
species can be formed that are damaging to the tissue (Figure 1.5).  Metabolism of 
anthracyclines reduces the drug to a semiquinone which can react with molecular oxygen 
creating superoxide species.  This quinone group can undergo many re-dox cycles.50  
These free radical species have been implicated in the development of cardiotoxicity 
during anthracycline treatments.  Plausible mechanisms include free radical peroxidation 
of membrane lipids leading to the damage seen in sarcoplasmic reticulum observed 
during anthracycline therapy.51  
The quinone structure is believed to cause cardiotoxicity by disrupting the 
calcium balance in the heart tissue.  There are two prevailing ideas about the mechanism 
that causes this: free radical formation or a mechanism independent of quinone derived 
free radicals.  It has been demonstrated that the quinone structure is necessary for 
daunorubicin induced cardiotoxicity.  This cardiotoxicity causes impairment of calcium 
release in the sarcoplasmic reticulum but does not involve free radical damage.  In studies 
done by Shadle the effects of daunorubicin, a quinone containing species, and 5-
iminodaunorubicin, a non-quinone containing analog, were compared.52  They found that 
the 5-iminoduanorubicin was less effective at causing cardiac damage than the 
daunorubicin drug suggesting that the quinone structure is necessary for cardiotoxicity.  
This study implies that this mechanism of cardiotoxicity involves the quinone moiety but 
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is independent of free radical formation and that this mechanism disrupted the calcium 
balance in the heart tissue.52   
Others have shown that the single electron re-dox cycling known to occur with 
the  quinone in anthracyclines may contribute to anthracycline cardiotoxicity.53  In a later 
study, it was established that as doxorubicin exposure in cells increased the superoxide 
anion formation also increased.  This study provides a link for drug exposure to the 
formation of free radicals that may be toxic to cells.20 
Oxygen free radicals are not the only free radicals that are formed during 
anthracycline treatments.  Tissues are also at risk of the formation of hydroxyl radicals 
when in the presence of hydrogen peroxide and iron.  It is believed that in the 
mitochondria, at Complex I, the anthracycline initially undergoes reduction to form a 
semiquinone species.  In the mitochondria the anthracycline is an electron acceptor for 
the electron transport chain (Figure 1.9).50  This semiquinone goes on to react with 
molecular oxygen to form a superoxide radical as well as hydrogen peroxide.53  The 
hydrogen peroxide will go on to react with iron in the cell to create hydroxyl radicals that 
are damaging to tissues.20  This cascade of events may be especially damaging to heart 
tissue versus other organs in the body because the heart is poorly defended against 
hydroxyl radicals.  The heart uses two main enzymes to detoxify oxygen free radicals: 
superoxide dismutase and selenium-dependent glutathione peroxidase.  Doxorubicin 
treatment can decrease the concentration of the selenium dependent glutathione 
peroxidase leaving the heart tissue vulnerable to the buildup of hydrogen peroxide and 
lipid peroxides.54  The hydrogen peroxide can further react with iron in the cell creating 
  25 
hydroxyl radicals that lead to alterations in calcium homeostasis in mitochondria or 
sarcoplasmic reticulum.20    
 Carbon-13 Metabolism is Linked to Cardiotoxicity 
Recent research has focused on the metabolism of the C-13 carbonyl of the 
anthracycline parent drugs.  Anthracyclines are believed to be metabolized by several 
different enzymes in the body.  One important enzyme is human carbonyl reductase 1 
(HCBR 1) which is believed to have activity on the quinone and C-13 carbonyls in the 
drug molecule.  Cells that are exposed to anthracyclines show an up-regulation of the 
enzyme HCBR 1 which has been shown to reduce the parent compound to the metabolite.  
The metabolite is much less efficient at killing tumor cells and has been shown to be 
much more cardiotoxic than the parent anthracycline (Figure 1.11).44  A detailed 
discussion of the anthracycline metabolism by HCBR 1 is provided later.   
Figure 1.11: Structure of the Anthracycline Metabolite 
 
     
Anthracyclines are believed to be metabolized by the enzyme HCBR 1.  The result is a cardiotoxic 
metabolite that is damaging to tissues and lacks cytotoxic properties.  Daunorubicinol: R = CH3, 
Doxorubicinol: R= CH2OH.3 
 
Anthracycline Alcohol Metabolites are Linked to Cardiotoxic Side Effects 
 Other theories about cardiotoxicity rely on the formation of oxygen free radicals 
as the underlying cause to heart tissue damage.  However, studies that have employed 
free radical scavengers have failed to prevent cardiotoxic damage at the time of 
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anthracycline administration.  This finding inspired a study done by Olson and coworkers  
to see if another mechanism played a role in cardiotoxicity.55   
 This study found that doxorubicinol is more cardiotoxic to the heart tissue than 
the parent drug doxorubicin.  Doxorubicinol depressed systolic myocardial function in 
heart muscle cells, inhibited calcium pump activity and sarcoplasmic reticulum lost the 
ability to store calcium in the heart.  Administration of the parent drug doxorubicin did 
not show any of these acute effects.55   
 They also measured the ability of the heart to convert doxorubicin to 
doxorubicinol and found that within 45 minutes a substantial amount of doxorubicinol 
was formed.  They believed that this metabolism was important to cardiac accumulation 
of doxorubicinol.  They also measured the ability of the metabolite to kill cancer cells and 
found that doxorubicin was 5 to 28 times more cytotoxic than the metabolite.55          
 This study lends support to the idea that a mechanism other than free radical 
formation and damage leads to cardiotoxic side effects.  This study provides evidence 
that the parent drug doxorubicin accumulates in the heart and that the heart has the ability 
to convert the drug to doxorubicinol.  Furthermore, Olson provides evidence that as the 
metabolite builds in the heart a toxic threshold is meet and damage is done to ion pumps, 
sarcoplasmic reticulum organelles and systolic action of the heart is inhibited.55 
Human Carbonyl Reductase 1: A Carbonyl Reducing Enzyme Found in the Body   
History of Human Carbonyl Reductase 1 
Human carbonyl reductase 1 (HCBR; EC 1.1.1.184) is an enzyme that is a 
member of the short chain dehydrogenase family (SDR) which contains a conserved 
amino acid region shared by members of this family.56  The NADPH binding domain 
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contains a Rossman fold with a conserved region GlyXXXGlyXGly (where X is any 
amino acid) in residues at positions 12-18.  Another conserved region of SDR families is 
a TyrXXXLys sequence.  The C-terminal portion of the enzyme has the lowest amount of 
homology and may play a role in determining substrate specificity for the carbonyl 
reductase enzymes.56 In the cell there are other carbonyl reducing enzymes that belong to 
a separate family called the aldo-keto reductase superfamily.  At one time HCBR 1 was 
included in this family but was moved to the SDR family when it was found to have more 
homology with members of this family. 
HCBR 1 catalyzes the NADPH dependent reduction of a wide variety of carbonyl 
groups.  Known substrates include aromatic hydrocarbons, aldehydes, ketones, quinones 
and pharmaceuticals such as anthracyclines. These substrates range from those 
endogenous to the body to several xenobiotic molecules that contain carbonyl groups.  
Menadione is considered an excellent substrate and is often used as a model substrate in 
studies of carbonyl reductase.  Catalytic amino acids include Ser 139, Tyr 193, and Lys 
197.  These amino acids help to transfer a hydride from the NADPH molecule to the 
carbonyl carbon of the substrate and a proton to the developing alcohol metabolite.56 
HCBR 1 is monomeric with a molecular weight of 30.3 kD and is found in the 
cytosol of the cell.  The gene encoding for HCBR 1 is located on chromosome 21 
(21q22.12) and codes for a 277 amino acid protein.  The enzyme is expressed in a wide 
range of tissues, including brain, liver, heart, skin, and placenta.  Variants of carbonyl 
reductase are found throughout nature in many different taxa.57  
Humans have two CBR genes, one that codes for HCBR 1 and one that codes for 
HCBR 3.  HCBR 3 is 62 kb downstream from HCBR 1 on chromosome 21.  HCBR 3 
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function has not been clearly identified as of now but is currently being investigated.56  
Other organisms have a gene encoding for carbonyl reductase 2; however, this gene is 
lacking in humans.    
Possible Functions of HCBR 1 
 Carbonyl reductase is believed to be involved in a variety of cellular processes 
such as the metabolism of several endogenous compounds, detoxification of exogenous 
carbonyl compounds, drug resistance, and signal transduction.  However, a definitive role 
for carbonyl reductase in humans is not well defined.56      
 HCBR Detoxifies Quinone Containing Compounds in the Body 
 It has been found that in vitro, HCBR shows activity on several quinone 
containing compounds which are known to be a source of oxidative stress and therefore 
are considered toxic in the body.  It is hypothesized that HCBR 1 metabolism protects the 
body from oxidative stress.  Quinone containing compounds that are not reduced can 
undergo enzyme-catalyzed single electron re-dox cycling leading to the generation of 
superoxide anion and other free radicals that are damaging to tissues.  The role of 
detoxifying quinones by HCBR 1 has not been directly observed in human tissues; 
however, HCBR 1 shows a high specificity for quinone containing compounds in in vitro 
studies.58   
HCBR 1 May Reduce Prostaglandins and Steroids in the Human 
Carbonyl reductase has also been shown to reduce prostaglandins and steroids  in 
vitro as well.59   However, it is unclear if this observed activity has  physiological 
relevance because carbonyl reductase has low catalytic efficiencies for these substrates.60             
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 A Possible Neuroprotective Role for HCBR 1 – The Reduction of 4-Oxononenal 
 in the Brain 
 
 HCBR 1 may have different physiological roles depending in which tissue it is 
located.  In the brain tissue HCBR 1 is hypothesized to play a neuroprotective role.  4-
Oxonon-2-enal is a product of lipid peroxidation and is a brain neurotoxin.  Carbonyl 
reductase has been shown to reduce this compound60 to the less reactive 4-hydroxy-2-
nonenal and this metabolism may be protective for the brain tissue.60   
 The central nervous system can be vulnerable to oxidative stress because of its 
high concentration of oxygen and lipids and low antioxidant defenses.  A recent study 
with Drosophila melanogaster has found that a CBR gene, called sniffer, may play a role 
in detoxifying 4-oxonon-2-enal, a product of lipid peroxidation, which reduces neuronal 
damage in normal brains.  This sniffer gene has a large homology with human carbonyl 
reductase and is only expressed in the brain, specifically in the entire cortex, where all 
neuronal cell bodies are localized.  Flies with mutations in the CBR gene had a shorter 
life span and showed neurodegeneration while flies that over expressed CBR were 
protected from neuronal damage caused by oxidative stress.  By reducing 4-oxonon-2-
enal in the brain tissue, HCBR 1 may contribute to the protection of the brain from 
diseases that result from oxidative stress such as Alzheimer’s, Parkinson’s or 
Huntington’s disease.61   
 HCBR 1 has a wide variety of potential physiological substrates indicating that 
the function of CBR in the body may be complicated.  Further study needs to be done to 
better define its physiological role.   
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Kinetic Mechanism of HCBR 1 
 Kinetic analysis done by Bohren et al. establishes that HCBR has a sequential 
ordered Bi Bi kinetic mechanism which is a common mechanism found in NADPH 
dependent dehydrogenase families (Figure 1.12).57  The coenzyme NADPH, binds to the 
enzyme first and the substrate carbonyl binds to the enzyme second.  The resulting 
product alcohol is released before NADP+.  There are three types of HCBR and this study 
also found that all three forms of enzymes have the same kinetic mechanisms.57  
  
Figure 1.12  Ordered Bi Bi Kinetic Mechanism Proposed for Human Carbonyl 
Reductase.   
 
  
E represents enzyme, A is the NADPH, B is the carbonyl substrate (anthracycline), P is the product 
alcohol, and Q is NADP+.  Lower case “k” is the rate constant for the step.  In this mechanism, NADPH 
binds before the carbonyl substrate and NADP+ is release after the product alcohol. 
 
  
The reaction catalyzed by HCBR 1 is a 2 electron reduction reaction, whereby the 
carbonyl is converted to an alcohol (Figure 1.13).  The hydride on the C4 position of the 
nicotinamide ring of NADPH is transferred to the carbonyl carbon of the substrate 
followed by the transfer of a proton via a proton relay system on the enzyme to the 
developing alkoxide, thus yielding an alcohol metabolite.   
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Figure 1.13 Re-dox Reaction of HCBR 1, NADPH and Carbonyl Substrate 
 
 
HCBR 1 mediates the re-dox reaction of carbonyl compounds.  A hydrogen is transferred from the NADPH 
molecule to the carbonyl group.  The result is an alcohol metabolite. 
 
 
Human Carbonyl Reductase 1: Metabolism of Anthracyclines is Linked to 
Cardiotoxicity 
 
HCBR 1 Metabolizes Anthracyclines 
 
 Several studies have implicated HCBR 1 in the metabolism of 
anthracyclines.1,49,62  This metabolism of carbon 13 leads to an alcohol product that is 
damaging to heart tissue.56,63,64  Single electron re-dox cycling of the quinone carbonyls 
can lead to the production of free radicals that are hypothesized to be damaging to tissues.  
Recent studies have found that HCBR 1 can reduce these carbonyls as well and may 
affect the generation of quinone derived reactive oxygen species.49 Given that HCBR 1 
reduces both the carbonyl at C13 and the quinone carbonyls, the extent to which HCBR 1 
participates in the complete metabolism of anthracyclines needs to be better understood. 
In a study done by Loveless it was found that all mammalian tissues catalyzed the 
reduction of daunorubicin.62  Daunorubicin is a preferred substrate than doxorubicin for 
the HCBR 1 enzyme reflected by the increased kcat/Km values for daunorubicin (Table 
1.1).49  All tissues showed activity on the anthracycline drugs; however, their efficiencies 
did differ depending in which tissue it was found.62     
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Table 1.1: HCBR 1 Kinetic Properties of Two Anthracycline Substrates 
 
  Daunorubicin Doxorubicin 
kcat (s-1) 1.27(0.03) 0.27(0.02) 
Km(µM) 108(7) 90(16) 
kcat/Km(µM-1s-1) 1.18(0.05)x10-2 2.90(0.3)x10-3 
Two anthracycline drugs show very different catalytic properties when metabolized by HCBR 1.  These 
differences are apparent even though there is a small difference in structure for these two drugs: they only 
differ by one hydroxyl group on the Carbon 14 (Figure 1.1).49 
 
Carbon 13 Metabolism of Anthracyclines by HCBR 1 
Two studies have linked human carbonyl reductase levels to the development of 
cardiomyopathies in mice models.64,65  In one study transgenic mice over expressed 
human carbonyl reductase in the mouse heart.65  Expressing mice developed severe 
cardiomyopathies and had enlarged hearts compared to normal non-expressing mice.  
Immunohistochemical staining of the heart tissue of expressers showed that HCBR 1 
expression was uniform, abundant and occurred in myocytes of the heart.  More 
importantly after a single injection of doxorubicin expressers converted 82% of 
doxorubicin to doxorubicinol compared to only 5% of non-expressers.  This result 
correlated the increased concentration of HCBR 1 with that of the increased 
doxorubicinol formation in the heart.  Doxorubicinol formation was correlated to heart 
damage in expressers by a serum creatine study.  Elevated levels of creatine kinase are 
linked to muscle damage.  Expressers were found to have 60% elevated creatine levels 
than nonexpressers indicating muscle damage.63 
 A second study involving carbonyl reductase knockout mice demonstrated that 
lower CBR levels lead to protection against anthracycline cardiotoxicity.64  They found 
that CBR1 (+/-) mice had lower levels of CBR and were protected from cardiotoxicity 
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after exposure to doxorubicin.  The knockout mice showed a decrease in circulating 
metabolite after exposure to doxorubicin compared to normal (+/+) mice. It is believed 
that the lower amount of CBR enzyme leads to less conversion of parent compound to 
metabolite.64   
 A recent study provides a partial explanation for the varied response to 
anthracycline cardiotoxicity observed in patients.  Gonzalez-Covarrubias et. al. examined 
the properties of a natural polymorphism in the human carbonyl reductase one (HCBR 1) 
gene.66  They found that between different human populations there is a variation at 
position 88 whereby some people have a valine and others have an isoleucine.  This site 
is associated with the NADPH binding in the active site of HCBR 1.  This study found 
that the two different forms of HCBR 1 had different Km and Vmax values for 
daunorubicin.  They also found that those with a valine at 88 had an increase production 
of doxorubicinol when exposed to doxorubicin.  The results of this study suggests that 
those with the valine 88 polymorphism may be more at risk of anthracycline-associated 
cardiotoxicity than those with isoleucine 88 due to the substantial increase in metabolite 
formation after exposure to doxorubicin.66  Also this study shows the rational in studying 
HCBR 1 by mutating key binding amino acids in the active site.  Different 
polymorphisms of HCBR 1 may display different specificities and kinetics for its 
substrates thus revealing information about substrate binding and catalytic mechanism for 
carbonyl reduction.  This information can be exploited to design a more effective, less 
cardiotoxic anthracycline analog.  
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Specific Aims of this Project 
Specific Aim 1:  Molecular Modeling of HCBR 1 and Known Substrates  
 Using the crystallized structure of the HCBR 1 enzyme and structures of the 
anthracyclines I will study the relationship between the enzyme and its substrates.  The 
crystallized structure of HCBR 1 has been solved and can be accessed through the RCSB 
Protein Data Bank using the accession number, 1wma.  This structure shows the enzyme 
complex with the cofactor NADP+ and an inhibitor bound in the active site.  This allows 
for the structures of various substrates like menadione, daunorubicin and doxorubicin to 
be aligned in the active site.  Analyses can be done to determine which amino acids in the 
HCBR active site appear to interact with the substrates and possibly play a role in 
substrate binding and orientation.   
Specific Aim 2:  Design a New Expression Vector for HCBR 1 
In order to facilitate purification of mutated forms of HCBR 1 a poly-histidine tag 
will be added to the C-terminus of the protein to facilitate purification.  Introducing 
mutations into a protein has the potential to inactivate or alter the protein structure of the 
enzyme and this purification system should allow for quick purification of the enzyme 
regardless of its condition after purification.  Specific aim 2 will address these problems 
by designing a new expression vector utilizing a histidine tag added to the protein.  The 
protein will now be purified by a Ni2+ resin and visualization of the enzyme can be done 
easily with a SDS-PAGE gel analysis.  
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Specific Aim 3:  Evaluate the Role of Met 234 in Doxorubicin vs. Daunorubicin 
Specificity 
 
Due to the information gained in specific aim one, specific amino acids in the 
HCBR 1 enzyme were chosen to undergo mutation.  I targeted position 234 which has a 
native methionine.  It is hypothesized that this amino acid provides steric hindrance with 
substrates in the active site.  It is believed that by mutating the 234 amino acid to amino 
acids with smaller side chains, such as Ala, Cys, or Ser, that more room will be generated 
in the active site.  I expect to see increased affinity for substrates that will be measured by 
an increased catalytic efficiency for substrates. 
Statement of Hypothesis 
Anthracyclines undergo metabolism by HCBR 1 in the body and I believe that 
there are key amino acids that determine substrate specificity and help guide substrates 
into the active site.  I hypothesize that methionine 234 prevents the binding of different 
anthracyclines due to a steric hindrance with side chains of anthracyclines.  For instance, 
daunorubicin has a higher specificity for HCBR 1 than doxorubicin.  Modeling studies 
show that the longer side chain of doxorubicin is partially hindered by its interaction with 
Met 234.  Such an adverse interaction is not observed with daunorubicin.  If this amino 
acid is mutated to smaller amino acids than more room will be generated in the active site 
and an increased catalytic efficiency will be observed for the doxorubicin molecule 
compared to the daunorubicin molecule.  
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Summary 
 Carbonyl reductase plays a significant role in metabolizing anthracyclines, 
lowering cytotoxic properties and increasing cardiotoxic properties of the drug and 
should be a pharmacological target for improved drug design.  By understanding the 
relationship between HCBR and its substrates a drug can be designed that resists 
metabolism and lowers anthracycline cardiotoxicity.  Targeting HCBR can increase the 
drugs lifespan in the cell and improve cytotoxic properties of the drug.  In order to design 
these new anthracycline treatments a better understanding of the kinetic mechanism of 
substrate recognition and substrate binding is needed.  Ultimately a drug will be designed 
that is a poor substrate for HCBR and resists metabolism and/or novel inhibitors will be 
identified that can block HCBR activity during anthracycline administration.  
 In light of the evidence that anthracycline combination therapies can be highly 
effective at treating certain cancers it is clear that resolving the cardiotoxic problems can 
be an important improvement to cancer therapies.  This study can provide further 
information about anthracyclines and their metabolism by a key enzyme.  This 
information can be used to enhance the cytotoxic properties and reduce risk of heart 
tissue injury during therapy.  New drug designs are important to providing care for 
patients that would otherwise be turned down for treatment.
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CHAPTER 2 
MATERIALS AND METHODS 
Materials 
Menadione was from Aldrich Chemical Company (Milwaukee, WI), and rutin 
were obtained from Sigma Chemical Company (St. Louis, MO). Reduced β-nicotinamide 
adenine dinucleotide phosphate, sodium salt, 99% (NADPH) was purchased from Life 
Science Resources (Milwaukee, WI). Doxorubicin HCl and daunorubicin HCl were from 
Pharmacia &Upjohn Co. (Kalamazoo,MI) and Bedford Laboratories (Bedford, OH), 
respectively.  
Molecular Modeling of Crystallized HCBR 1 Enzyme 
Crystallized Structure of HCBR 1 
 The HCBR 1 enzyme has been crystallized and can be accessed at the Protein 
Data Bank, www.rcsb.org/pdb, with the accession number 1WMA.67  The structure has a 
bound inhibitor molecule and a bound co-enzyme molecule (NADPH) present in the 
model.   
Analyzing Active Site of Crystallized HCBR 1 
 The crystallized structure was viewed with the WinCoot program, version 0.3.3, 
http://www.ysbl.york.ac.uk/~lohkamp/coot/wincoot.html.  The structure of doxorubicin 
was downloaded from the RCSB Protein Data Bank, accession number 1D12.  Using the 
bound inhibitor as a model for the position of the anthracycline C-13 carbonyl, 
doxorubicin was aligned in the enzyme active site so that the carbonyl was placed near
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the known catalytic amino acids described in chapter one.  The structure was analyzed for 
amino acids that appear to interact with the substrate.  Amino acids that were less than 3 
Å from the substrate were of interest.  This distance is within that expected for hydrogen 
bond interactions.   
Creation of an Expression System for HCBR 1 
Amplification and Ligation of Human Carbonyl Reductase 1 Gene into pTrcHis2 TOPO 
Vector 
 
The HCBR 1 gene, formally isolated from the liver, was PCR amplified from the 
HCBR 1 pET5a construct previously reported by Slupe et. al.49  The forward primer was 
5’- GAATTCATGTCGTCCGGCATCCATGTAG-3’ and the reverse primer was 5’-
CCACTGTTCAACTCTCTTCTCTGA-3’.   
   The amplified PCR product was incubated with the pTrcHis2 TOPO vector at 
room temperature for 5 minutes.  The resulting ligation mixture was transformed into 
Invitrogen One Shot Top10 E. coli cells and grown in SOC media in a shaker set at 37oC 
and 225 rpm for thirty minutes.  The growth was plated onto Luria-Bertani (LB) agar 
plates supplemented with 100µg/mL of ampicillin and placed in a 37oC incubator 
overnight.  The resulting colonies were counted on the following day (Table 2.1).   
Table 2.1: Ligation of HCBR 1 Gene and pTrcHis2 TOPO Vector 
 
Volume of Ligation 
Mixture 
Number of 
Colonies 
25µL 7 
50 µL 19 
100 µL 37 
115 µl 19 
Ligation mixtures were inoculated into Top10 E. coli cells and were plated onto LB plates supplemented 
with 100 µg/ml ampicillin and left to grow overnight in 37oC oven.   
 
  39 
Colonies were chosen and used to inoculate 3 mL LB-AMP broth, and allowed to 
shake at 225 rpm overnight at 37oC.  Plasmids were isolated from these growths with the 
Eppendorf Fast Plasmid Mini standard procedure.  Plasmids were screened for the correct 
gene orientation using a restriction enzyme digests with EcoRI.  The digests were 
analyzed by gel electrophoresis using a 1% agarose gel.  Correct orientation resulted in 
two bands: 5 kb and 850 base pair in the lane.  From this point forward the HCBR 1 gene 
with histidine tag will be referred to as HCBR 1'. 
Protein Expression of Native HCBR 1' and Expression of the Recombinant Protein 
 
 E. coli Growths of Native HCBR 1' 
 Native HCBR 1' plasmids were transformed into Invitrogen One Shot Top10      
E. coli cells and plated onto LB-AMP plates.  These plates were placed in 37oC incubator 
overnight.  One colony was used to restreak another LB-AMP plate and the resulting 
colonies were used to inoculate an overnight 3 mL LB-AMP culture.  After growing for 
about 12 hours with shaking at 37oC, the culture was added to a 50 mL LB-AMP culture 
and allowed to grow with shaking overnight at 37oC.  The following morning the 
overnight culture was used to inoculate 4.8 L of LB-AMP broth.  Once the OD600 reached 
0.6, IPTG was added to a final concentration of 1 mM.  The induced cells were grown for 
another 12 h before they were harvested by centrifugation at 5000 x g. 
 Purification of Native HCBR 1'  
 The cell pellet was re-suspended in a 1 mM imidazole, 50 mM NaPO4 buffer, pH 
8.0 and sonicated in an ice water bath using a Misonix Sonicator 3000.  The cell 
suspension received 10 x 30 second pulses at a power setting of 7.  A 3 minute rest period 
was allowed between pulses.   The resulting crude lysate was centrifuged at 50,000 x g 
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for sixty minutes using a Sorvall Evolution refrigerated centrifuge.  The resulting 
supernatant was retained and was diluted 1:4 with a 1 mM imidazole, 50 mM NaPO4 
buffer, pH 8.0.  Approximated 1-2 mL of Talon Ni2+ resin was poured into a column and 
equilibrated with the same buffer.  The diluted lysate was added to the resin followed by 
a wash with a liter of 1 mM imidazole, 50 mM NaPO4 buffer, pH 8.0.   
The protein was eluted from the resin with increasing imidazole concentrations in 
a 50mM NaPO4 buffer, pH 8.0.  The four elution buffers used have the following 
imidazole concentrations: 1 mM, 50 mM, 250 mM, and 1 M imidazole. 
 SDS-PAGE Analysis, Concentration, and Buffer Exchange. 
 The elution fractions were analyzed for protein using 12% sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) to locate the HCBR 1' protein.  The 
protein of interest eluted from the column in the 50 mM imidazole, 50 mM NaPO4 buffer, 
pH 8.0.  The fractions containing the HCBR 1’ protein were concentrated and buffer 
exchanged to 100 mM sodium phosphate, pH 7.0.   
Creation and Characterization of the M234C HCBR 1´  
 
Creation of Mutated Human Carbonyl Reductase 1 Gene Constructs 
 
 Site-Directed Mutagenesis 
 
 The QuickChange site-directed mutagenesis kit by Stratagene (Cedar Creek, TX) 
was utilized to mutate the HCBR 1 gene.  The amino acids that were targeted were 
methionine 234, methionine 141, and tryptophan 229.  This method mutates a native gene 
in a vector by utilizing complimentary primers that contain a mutation.  As such the 
entire plasmid is copied during the process.   
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Primer Design 
 
The sequence for the native HCBR 1 gene (P16152) was downloaded from the 
ExPaSy Proteomics Server (http://www.expasy.org).  The codons coding for amino acids 
Met 141, Met 234 and Trp 229 were located.  Table 2.2 lists the primer sequences that 
were designed to mutate these amino acids to alanine, cysteine, or serine.   
Table 2.2: Primer Sequences for the QuickChange Mutagenesis Procedure 
 
Intended 
substitution 
A.A. 
Position 
Forward Primer Sequence Reverse Primer Sequence 
Met  Ala 141 5'GTG GTG AAC GTA TCT AGC ATC 
GCG AGC GTC AGA GCC CTT AAA 
AGC 3' 
5' GCT TTT AAG GGC TCT GAC GCT 
CGC GAT GCT AGA TAC GTT CAC 
CAC 3' 
Met  Ser 141 5' GTG GTG AAC GTA TCT AGC ATC 
TCG AGC GTC AGA GCC CTT AAA 
AGC 3' 
5' GCT TTT AAG GGC TCT GAC GCT 
CGA GAT GCT AGA TAC GTT CAC 
CAC 3' 
Met  Cys 141 5' GTG GTG AAC GTA TCT AGC ATC 
TGC AGC GTC AGA GCC CTT AAA 
AGC 3' 
5' GCT TTT AAG GGC TCT GAC GCT 
GCA GAT  
GCT AGA TAC GTT CAC CAC 3' 
Met  Trp 141 5' GTG GTG AAC GTA TCT AGC ATC 
TGG AGC GTC AGA GCC CTT AAA 
AGC 3' 
5' GCT TTT AAG GGC TCT GAC GCT 
CCA GAT GCT AGA TAC GTT CAC 
CAC 3' 
Met  Ala 234  5’ 
GGGTGGGTGAGAACTGACGCGGCGG
GACCCAAGGCC 3’ 
 5’ GGC 
CTTGGGTCCCGCCGCGTCAGTTCTCA
CCCACCC 3’ 
Met  Cys 234  5’ 
GGGTGGGTGAGAACTGACTGCGCGG
GACCCAAGGCC 3’ 
 5’ 
GGCCTTGGGTCCCGCGCAGTCAGTTC
TCACCCACCC 3’ 
Met  Ser 234  5’ 
GGGTGGGTGAGAACTGACTCGGCGG
GACCCAAGGCC 3’ 
 5’ 
GGCCTTGGGTCCCGCGCAGTCAGTTC
TCACCCACCC 3’ 
Met  Trp 234 5' CCA GGG TGG GTG AGA ACT GAC 
TGG GCG GGA CCC AAG GCC ACC 3' 
5' GGT GGC CTT GGG TCC CGC CCA 
GTC AGT TCT CAC CCA CCC TGG 3' 
Trp  Ala 229 5' CTG AAT GCC TGC TGC CCA GGG 
GCG GTG AGA ACT GAC ATG GCG 3' 
5' CGC CAT GTC AGT TCT CAC CGC 
CCC TGG GCA GCA GGC ATT CAG 3' 
Trp  Ser 229 5' CTG AAT GCC TGC TGC CCA GGG 
AGT GTG AGA ACT GAC ATG GCG 3' 
5' CGC CAT GTC AGT TCT CAC ACT 
CCC TGG GCA GCA GGC ATT CAG 3' 
Primers were designed to mutate key amino acids in the native HCBR 1 gene sequence.  The sites of 
interest are Met 234, Met 141 and Trp 229.  The letters in the bold underlined font represent the mutated 
codons in the primer. 
 
Primers were designed according to the recommendations of Stratagene for the 
QuickChange II site-directed mutagenesis kit: 
1) Mutation is designed into the primer and located in the middle of the primer 
with approximately 15 bases flanking both sides of the mutation.  The primer ends in a G 
or C base.  The primers anneal to the same sequence on the opposite DNA strands. 
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2) Primers were designed with a melting temperature of greater than 78oC.  The 
melting temperature calculation is:  
( ) mismatch
N
GCTm %
675%41.05.81 −−+=
 
N = primer length in bases 
 
Thermocycling Parameters 
 
Following the protocol provided in the QuickChange II site-directed mutagenesis 
kit by Stratagene, the following were added to a 1.5mL centrifuge tube: approximately 50 
ng of DNA, 100 ng of forward and reverse primer, dNTP’s, and 1.25 Units of DNA 
polymerase.  The reactions were placed in a thermocycler.  The PCR thermocycling 
settings are listed in the following table. 
Segment Cycles Temperature Time 
1 1 95oC 30 seconds 
2 16 95oC 30 seconds 
  55oC 1 minute 
  68oC 5minutes 
 
After the PCR thermocycling was complete the reactions were placed on ice for two 
minutes. 
 Removal of Native HCBR 1' Plasmids 
 
In order to remove the plasmids containing the native HCBR 1 gene 0.5µL of 
DPN1 restriction enzyme (10 U/µL) were added to each PCR reactions, pipetting 
thoroughly to mix.  The DPN1 restriction enzyme recognizes methylated plasmids.  Only 
the native plasmids have methylated sites and are recognized by the DPN1 restriction 
enzyme and these plasmids will undergo digestion.  This leaves a population of mutated 
plasmids behind.   
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The digestion reactions were micro-centrifuged at 7,000 x g and air bubbles were 
removed.  The DPN1/QuickChange II reactions were incubated at 37oC for 1 hour.  After 
a one hour digestion the PCR product was transformed into Stratagene XL1- Blue 
Supercompetent E. coli cells and were plated on LB-AMP plates and incubated at 37oC 
overnight. 
Plasmid Prep Procedure 
 
Five colonies of each mutation were selected to undergo plasmid preparation and 
these plasmids were sequenced.  The Promega PureYield Plasmid Midiprep System was 
utilized and the standard DNA purification protocol was followed.    
Gene Sequencing 
 
The mutated plasmids were sent into Genewiz Laboratory, Genewiz inc, (South 
Plainfield, NJ) for sequencing.  The HCBR 1 gene was sequenced using the following 
pTrcHis2 TOPO primers: Forward 5’ GAGGTATATATTAATGTATCG 3’, Reverse 5’ 
GATTTAATCTGTATCAGG 3’.  These primers bind the vector in the flanking regions 
surrounding the HCBR 1 gene.  The resulting sequencing information was analyzed using 
the Bioedit, version 7.0.0, software program.    
An HCBR 1 gene sequence used for comparison was created from the sequence 
available at Expasy.org (accession number P16152), and the bases for the histidine tag 
were added to the end of the gene according to the manual provided for the pTrcHis2 
TOPO vector system.  This sequence was then used to align with the plasmid sequences.  
When the gene was located it was analyzed for the gene mutation coding for the mutated 
amino acids.  The rest of the gene was analyzed to confirm that no other unattended 
mutations had occurred. 
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Mutant HCBR 1' Protein Expression and Purification  
 
 Protein Production  
 
 Sequenced HCBR' plasmids were transformed in Invitrogen One Shot Top10      
E. coli cells and grown as described above for the modified native protein. The protein 
was expressed and purified in a manner similar to that described for the native HCBR'. 
Kinetic Characterization of Native and Mutant Forms of HCBR' with Menadione 
Substrate 
 
Extinction Coefficient Determination 
 
 The extinction coefficient for the HCBR 1' were estimated using the ProtParam 
tools at http://ca.expasy.org.  The known HCBR 1 protein sequence was downloaded 
from the ExPaSy Proteomics Server, accession number P16152, and the extra amino 
acids from the pTrcHis2 TOPO vector were added to the sequence.  This sequence was 
entered into the ProtParam tools and an extinction coefficient of 0.668 mL·mg-1 at 280 
nm was estimated.  The mutation was added to the sequence and was found to have an 
extinction coefficient of 0.673 mL·mg-1 at 280 nm. 
Specific Activity Determination and Steady State Kinetic Analysis 
 
Reaction kinetics were measured by monitoring the change in NADPH 
concentration over time spectrophotometrically (ε340 = 6220 M-1cm-1) using a Varian 
Cary 100 Bio.68 Initial slopes of the progress curves were obtained from fitting the curves 
to either a line or a parabola, and these slopes were used to calculate the initial velocities. 
Specific activity for the modified native HCBR 1 enzyme in a standard assay comprised 
of 250 µM menadione and 50 µM NADPH in 100 mM sodium phosphate, pH 8.0 was 
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measured and compared to that previously published.49  The extinction coefficient 0.668 
mL·mg-1 was used to estimate protein concentration at 280 nm in a Cary 100 
spectrophotometer.  The volume of protein was varied from 3 µl to 10 µl of enzyme and 
the change in absorbance per minute was recorded.  Specific activity values were 
calculated for each trial.   
Menadione saturation kinetics were measured using 50 µM NADPH in 100 mM 
sodium phosphate and menadione concentrations ranging from 3µM to 200µM.  The 
resulting kinetics data were fit to the Michaelis-Menten equation (eq. 1) using the 
HYPERW program.69  
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Where νo is the initial velocity, Vmax is the maximal velocity, Km is the Michaelis 
constant, and A is the substrate concentration (in this case it is menadione).  From the 
estimates of these constants the kcat (catalytic rate constant) and the kcat/Km (catalytic 
efficiency) was calculated.  The M234C mutant protein was found to be inactive under 
the standard assay conditions, so several other assay conditions were investigated in an 
effort to detect a measurable enzyme activity.  Several concentrations of menadione and 
NADPH were investigated and the assay was monitored for up to 20 minutes.  Also, both 
daunorubicin and doxorubicin (300 µM concentrations were used for both) were tested as 
substrates.  Also, dithiothreitol (up to 1 mM) was also added to the assays in case the 
addition of an active-site cysteine led to unintended disulfide bond formation.  The total 
time for each assay measured up to 20 minutes.  
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Characterization of Coenzyme and Substrate Binding 
 
Binding of coenzyme and substrates were studied by fluorimetry.  A 4 µM 
solution of protein (either the native or mutant HCBR 1') was titrated with either 
NADPH, NADP+, daunorubicin, or doxorubicin (concentrations ranging from 0.50 µM to 
115 µM) and the resulting reduction in protein fluorescence was measured (Ex. 292 nm; 
Em. 333 nm) using an Olis DM45 spectrofluorimeter (Olis, INC., Bogart, GA).  The data 
was fit to the Stern-Volmer equation (eq. 2) and a Kd value was determined.  The 
program uses a modified Stern-Volmer equation to measure the disassociation of 
substrate and enzyme.  
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Where f1is the fraction of protein fluorescence that is quenched, B is substrate 
concentration and Kd is the dissociation binding constant for the substrate and enzyme. 
Circular Dichroism of Native and M234C HCBR 1' 
 
 Circular dichroism was done to assess changes in secondary structure between the 
native HCBR 1' and the M234C HCBR 1' proteins.  A far UV analysis was done on the 
samples which covered the 275 to 175 nm spectrum.  The spectropolarimeter was 
blanked with a 100 mM sodium phosphate
 
buffer, pH 7.0 and was subtracted from the 
data.  0.5 mg/mL solutions of both proteins were made and 200µL of solution was added 
to a 1 mm cell that was placed in a spectropolarimeter (Jasco J810).  Data was collected 
at 1 wavelength per second.  Two runs of three scans were collected.  Each run was 
averaged and then both runs were averaged.   
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The raw data was analyzed by comparing the wavelength to the ∆θ 
(mdeg/M*cm).  The data was corrected in order to account for any miscalculations in 
concentrations of the proteins.  The data was also analyzed by Dichroweb, 
http://www.cryst.bbk.ac.uk/cdweb/html/home.html, this website compares data to a 
database of known proteins.   
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CHAPTER 3 
 
RESULTS 
 
CREATION OF AN EXPRESSION SYSTEM FOR HCBR 1 
 
Ligation of HCBR 1 Gene into pTrcHis2 TOPO Vector 
 
The HCBR 1 gene was successfully amplified and inserted into the pTrcHis2 
TOPO vector in the correct orientation.  The histidine tag was added to the C-terminus of 
the gene.  Two extra amino acids were added to the N-terminus and twenty-nine amino 
acids were added to the C-terminus of the enzyme.  The results were verified by a 
restriction enzyme digest with EcoRI and resulted in two bands at 5kB and 850 bp.  The 
mutations were also confirmed by sequencing of the gene in the plasmid.   
Protein Expression of Native HCBR 1' 
 It was found that from a 4.8L culture 11 mgs of protein were obtained.  The 
protein was eluted from the nickel column with the lower than expected concentration of 
50 mM imidazole, in 50 mM sodium phosphate, pH 8.0.  At such a low concentration of 
imidazole buffer it seems apparent that the native HCBR 1' protein is weakly bound to 
the Ni2+ resin, perhaps because the C-terminal poly-histidine tag is partially obscured 
through interactions with the remaining protein.  Typically it is expected that elution will 
occur in the imidazole range of 250 mM to 1 M.  SDS-PAGE analysis adds more 
evidence that the protein of interest was obtained at > 90% purity.
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The molecular weight of the modified enzyme is estimated to be 33.80 kD.  The 
major protein band that occurs is slightly above the 33 kD band in the ladder indicating 
that the major band is in the correct region for the weight that is expected.  The gels have 
one major band occurring but there are two minor bands at 24 kD and 22 kD which 
comprise < 10% of the total protein.  The identity of these bands has yet to be 
determined, although they may be HCBR 1' proteins that have undergone degradation 
(Figure 3.1).   
Figure 3.1: SDS-PAGE Gel of NHCBR'  
 
 
Lane 1: Molecular Weight Ladder, EZ-run Prestained REC Protein Ladder (Fischer), Lane 2: 0.757mg/mL 
NHCBR' sample, Lane 3: 0.894 mg/mL NHCBR' sample.  The major band is located just slightly above 
33kD band in ladder, in the region that is expected.   There is a minor band at about 24kD and 22kD. 
 
 
Characterization of Native HCBR 1' with Menadione Substrate 
 
Specific Activity 
 
 The specific activity of the modified native protein was found to be 0.63 ± 0.08 
µmol/mg·min.  The reported specific activity in the standard assay for the HCBR 1 
pET5a enzyme is 5.1 ± 0.7 µmol/mg·min.49  The specific activity for the modified native 
protein is 8 fold less than that of the unmodified protein.  It is hypothesized that this 
lower value is due to the C-terminal peptide comprised of 29 amino acids including the 
histidine tag interfering with the active site in some way.  
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Steady State Kinetics Studies with the Modified Native HCBR    
Table 3.1 summarizes the steady state kinetic values for both the published 
unmodified HCBR enzyme49 and the His-tagged HCBR enzyme.  The Km for the His-
tagged enzyme was found to be 3.5 fold lower than the unmodified enzyme which 
indicates that this modified enzyme is reaching its maximal catalytic efficiency at lower 
substrate concentrations.  The kcat, turnover number, for His-tagged HCBR was seven 
fold lower than that of the unmodified enzyme, indicating that the modified enzyme 
produces much less product molecules in the same amount of time than that of the 
unmodified enzyme.  The value of kcat/Km, or catalytic efficiency, for the His-tagged 
enzyme is approximately half of that observed for the unmodified enzyme.  So this 
suggests that overall the His-tagged enzyme is two-fold less efficient in catalyzing the 
reduction of menadione as is the unmodified enzyme. This information also supports the 
idea that the histidine tag may somehow interfere with enzyme catalysis.   
Table 3.1: Steady State Kinetic Constants for NHCBR', M234C HCBR', and 
Published HCBR 1 pET5a.   
 
Enzyme Substrate kcat, s-1 Km, µM 
kcat/Km,  
µM-1s-1 
NHCBR' Menadione  0.53 ± 0.02  11±2  0.049 ± 0.007 
M234C HCBR' Menadione None None None 
HCBR 1 pET5aa Menadione 3.7 (0.1) 38 (3) 9.8 (0.5) x 10-2 
 (aData from pET5a is from Slupe 2005).49  The above kinetic constants were established for the three 
forms of the HCBR 1 enzyme.  There is a significant difference between the pET5a enzyme and the 
histidine tagged enzymes.  There is a significant difference between the NHCBR 1' and the M234C HCBR'. 
 
 All of the data collected for the steady-state kinetics indicate that when the 
histidine tag was added to the HCBR enzyme the efficiency of the enzyme to reduce the 
substrate menadione was diminished.  The substrate menadione has been used as a model 
substrate to study this enzyme’s catalytic process by several different researchers.  There 
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are many benefits to using menadione as a substrate as opposed to using the 
anthracyclines of interest.  These benefits include cost, ability to dispose and safety.  
Although steady state kinetics have yet to be completed using the anthracyclines it is 
hypothesized that lower catalytic efficiencies will also be observed with other substrates 
such as doxorubicin or daunorubicin for the His-tagged native enzyme. 
Characterization of Coenzyme and Substrate Binding 
  Due to the diminished activity of this modified enzyme, fluorimetry was used to 
look at independent binding of coenzymes and substrates to the active site.  Such a 
diminished catalytic efficiency and turnover number as seen for the His-tagged native 
enzyme could arise if either coenzyme binding or carbonyl substrate binding were 
disrupted.  These series of fluorimetry studies are trying to find information about which 
molecules show perturbations in enzyme binding. 
Native HCBR 1 enzyme has a tryptophan (Trp 229) in the active site of the 
enzyme that reports on binding to the enzyme active site.  As compounds bind the active 
site the fluorescence of the tryptophan is decreased.  Several coenzymes/substrates were 
examined.  The binding of NADPH was examined (Figure 3.2) and quenching of the 
enzyme was observed.  Each fluorescence value is divided by the fluorescence of just 
enzyme to yield the relative fluorescence, f/f0.  This calculation normalizes the data.   
NADPH is known to fluoresce in the same region as the HCBR enzyme.  Studies 
with NADP+ were done because this molecule does not fluoresce in the same region.  
NADP+ is known to bind the active site like NADPH.  Figure 3.3 shows the results of the 
NADP+ fluorimetry study.  It was expected that NADP+ quenching would mirror 
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NADPH quenching.  The ability to cause quenching for both of these molecules does 
appear to be different.   
Figure 3.2: Fluorescence Quenching of NHCBR 1' and NADPH Coenzyme 
 
Coenzyme binding ability was expolored with fluorescence quenching studies.  A 4µM NHCBR' solution 
was made and a 1mM solution of NADPH was added in 1µL increments.  The fluorescence values were 
recorded and graphed.  As the active site Trp 229 is quenched a decrease in fluorescence is observed. 
 
Figure 3.3: Fluorescence Quenching of NHCBR 1' and NADP+  
 
Coenzyme binding ability was expolored with fluorescence quenching studies.   A 4µM NHCBR' solution 
was made and a 1mM solution of NADP+ was added in 1µL increments.  The fluorescence values were 
recorded and graphed.  NADP+ is prefered for fuorescence because, unlike NADPH, it does not fluoresce in 
the same region has the NHCBR'. As the active site Trp 229 is quenched a decrease in fluorescence is seen. 
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Next the binding of anthracycline substrates were studied by fluorimetry.  There 
was a significant drop in fluorescence when daunorubicin was added to the assay (Figure 
3.4).  When doxorubicin was added to the assay there was a drop in fluorescence but not 
to the extent of the daunorubicin (Figure 3.5).   
The results of the fluorimetry studies have lead to the hypothesis that the histidine 
tag may potentially be interfering with the coenzyme binding site of the enzyme, 
although the details of that mechanism have not been elucidated.  
 
Figure 3.4: Fluorescence Quenching of NHCBR 1' and Daunorubicin 
 
Substrate binding ability was expolored with fluorescence quenching studies.  A 4µM NHCBR' solution 
was made and a 1.24mM solution of daunorubicin was added in 1µL increments.  The fluorescence values 
were recorded and graphed. As the active site Trp 229 is quenched a decrease in fluorescence is seen. 
 
 
 
 
 
 
 
 
 
  54 
 
 
Figure 3.5: Fluorescence Quenching of NHCBR 1' and Doxorubicin 
 
Substrate binding ability was expolored with fluorescence quenching studies.  A 4µM NHCBR' solution 
was made and a 1mM solution of doxorubicin was added in 1µL increments.  The fluorescence values were 
recorded and graphed.  As the active site Trp 229 is quenched a decrease in fluorescence is observed.   
 
  
Kd values were established for the coenzymes and substrates (Table 3.2).  These 
values reflect the disassociation of substrate from enzyme and can be represented by the 
following equation: 
][
]][[
C
SEK
SEC
d =
+↔
         (eq. 3)
 
 
C= Enzyme/substrate complex 
E= Enzyme 
S= Substrate 
 
The Kd value represents the concentration of substrate when half of the binding 
sites of an enzyme are occupied.  A smaller Kd value indicates a more tightly bound 
substrate.  The substrate has a higher affinity for the enzymes binding site than a substrate 
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with a larger Kd value.  The Kd value is not the preferable way to measure binding of 
substrates because substrates potentially can bind active sites without being in the optimal 
position for catalysis.   
 
Table 3.2: Kd Values for the Binding of Coenzyme and Anthracyclines to Native and 
M234C HCBR' 
Substrate Native Kd(µM) M234C Kd(µM) 
Doxorubicin 22.67 (19.62 - 26.16) 35.8 (31.8 - 40.0) 
Daunorubicin 25.45 (17.79 - 35.95) 31.5 (27.2 - 36.63) 
NADP
+ 5.49 (4.55 - 6.5) 19.53 (15.83 - 23.96) 
NADPH 13.58 (11.32 - 16.16 ) 26.83 (23.5 - 30.61) 
The binding of coenzymes and substrates were assessed by fluorimetry and resulting data were fit to the 
Stern-Volmer equation (eq. 3).  A smaller Kd value indicates higher affinity between active site and 
molecule.  This data suggests that for both coenzyme and substrates the NHCBR' active site may have a 
stronger affinity than the mutant.   The numbers in parentheses represent the 67% confidence interval. 
 
The scientific literature is lacking published Kd values for the unmodified enzyme 
and anthracycline substrate binding.  The data that was collected for the pTrcHis2 TOPO 
enzyme cannot be directly compared to the pET5a HCBR; however, information can still 
be gained as far as trying to identify which molecules exhibit impaired binding to the 
pTrcHis2 TOPO enzyme.  
Molecular Modeling of Crystallized HCBR 1 Enzyme 
Molecular modeling of the HCBR 1 enzyme and the doxorubicin molecule 
resulted in the identification of methionine 234 as an amino acid that potentially interacts 
with bound substrates and limits the size of the substrate that can fit in the active site 
(Figure 3.6).   
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Figure 3.6:  Models of Anthracycline Binding to the Active Site of Human Carbonyl 
Reductase   
 
 
 
 
 
 
 
 
 
 
 
 
Model of doxorubicin C13 carbonyl reduction by human carbonyl reductase showing the close contact 
between the side chain of doxorubicin and the methionine 234 amino acid.   
 
 
It was found that methionine 234 appears to interact with the C-13 side chain of 
doxorubicin (Figure 3.6) in such a manner as to obstruct proper binding and orientation in 
the active site required for optimal chemistry.  Daunorubicin which has a smaller C-13 
side chain does not appear to have such a conflict with Met 234.  This may be the reason 
why daunorubicin was found to be a better substrate for HCBR than was doxorubicin.49  
It is hypothesized that the Met 234 limits the binding of substrates in the active site 
because it sterically hinders the substrates.  The Met 234 is about 3Å away from the 
doxorubicin molecule which is about the distance for a hydrogen bond.   
It was found that mutating methionine 234 to serine, alanine or cysteine in a 
computer based model increased the space in the active site for the side chain of 
doxorubicin.  This increased distance is hypothesized to allow the doxorubicin more 
ability to bind in the active site without interference from other amino acids in the active 
site and thus allow for more optimal orientation in the active site. 
  57 
Trp 229 and Met 141 were also indentified as potentially important amino acids 
(Figure 3.7).  They appear to surround the aglycone structure of the anthracycline 
molecules.  The anthraquinone has two points that are 3Å away from both the Trp 229 
and Met 141.  It is hypothesized that these two amino acids help to stabilize the substrates 
when they are in the active site undergoing catalysis.  The mechanism of this stabilization 
has not been defined to the extent of the hypothesized interaction of Met 234 and 
substrate side chains discussed in this paper.  
 
Figure 3.7: Inhibitor Binding by Human Carbonyl Reductase   
 
 
 
 
 
 
 
 
 
 
 
An inhibitor is bound to the active site of HCBR. Met 141 and Trp 229 are designated by arrows and the 
inhibitor is blocked in.  The pyrazolopyrimidine ring of the inhibitor is sandwiched between Met 141 and 
Trp 229 side chains. 
 
Mutating Trp 229 and Met 141 to Ala, Ser or Cys in the computer model also lead 
to increased space in the active site.  The hypothesis is that this larger space will allow 
more space for the maneuvering of the substrate molecule leading to increased binding in 
the active site.    
 
 
 
Met 141 
Trp 229 
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Characterizing the M234C HCBR 1'  
Creation of Mutated Human Carbonyl Reductase 1 Gene Constructs 
 Site-Directed Mutagenesis of HCBR 1' 
Several mutated plasmids of the HCBR 1' gene were made (Table 3.3).  Several 
sites were targeted.  The methionine 234 site was successfully mutated to cysteine, 
alanine, serine and tryptophan. The methionine 141 site was successfully made into 
serine, tryptophan, alanine, and cysteine.  The tryptophan 229 site has not been mutated 
as of now.  One double mutant was created – S141/S229.  The large numbers of mutated 
colonies on the mutated plates was a good indication that the procedure was successful.  
The DPN1 control had the same concentration of native plasmid and underwent the PCR 
procedure without any primers followed by DPN1 digestion.  There were five or less 
colonies on theses plates indicating that the DPN1 restriction enzyme was able to digest 
all parental DNA in the PCR reactions.  Five colonies were chosen from each mutation 
and the plasmids were purified and the genes were sequenced.   
Table 3.4 summarizes the sequencing results of these plasmids.  Most plasmids 
contained the desired mutation although a small number of plasmids did not.  Some 
plasmids that were sent in did not result in a clear enough sequence for analysis which 
may be due to improper preparation of plasmid prior to sequencing.  At least one colony 
of each desired mutation was created and had the correct sequence for the rest of the 
gene.  The double mutated plasmid did not have a clear enough sequence to insure that 
both mutations are present.  They will need to undergo further sequencing to confirm the 
results.   
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Table 3.3: Results of the Quick Change Mutagenesis Procedure 
PCR Reaction 
Number of 
Plates Number of Colonies Expectations 
S141,E244 HCBR' 2 155 Hundreds  
A234,E244 HCBR' 2 195 Hundreds  
S 234,E244 HCBR' 2 398 Hundreds  
C234,E244 HCBR' 2 274 Hundreds  
DPN1 Control 2 less than 5 colonies None 
E. coli only Control  2                     None None 
 
PCR Reaction  
Number of 
Plates Number of Colonies Expectations  
Trp141,E244 HCBR' 2 18 Hundreds 
A141,E244 HBCR' 2 13 Hundreds 
S141, E244 HCBR' 2 136 Hundreds 
Trp234, HCBR' 2 6 Hundreds 
C141, E244, HCBR' 2 43 Hundreds 
DPN1 Control 2 
                                     
                            None None 
E. coli only control 2 
                               
                            None None 
Under optimal conditions the quick change mutagenesis protocol produces several hundred colonies of 
mutated plasmids.  The large number of plasmids that resulted in the mutated plates was good evidence that 
the mutations worked.  A DPN1 control utilized native template plasmid and underwent the DPN1 
digestion.  The low recovery of colonies indicates that the DPN1 was able to efficiently digest all native 
plasmids. 
 
Protein Expression 
 M234C HCBR 1' Protein Production 
 To better identify mutated enzyme production the HCBR 1 gene was inserted into 
the pTrcHis2 TOPO vector.  The advantage of adding a histidine tag to the gene allowed 
the enzyme to bind a Ni2+ column.  It helps in several regards, first it immediately 
separates bacterial carbonyl reductases from HCBR 1 and second it is easy to sample the 
fractions on an SDS-PAGE gel allowing the visualization of the mutated proteins 
regardless of activity. 
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 It was found that a 4.8L of culture yielded about 9.5 mg of mutated protein.  As 
with the native His-tagged construct, the protein eluted from the nickel column with the 
50 mM imidazole, 50 mM sodium phosphate, pH 8.0 buffer.  It also shows weak binding 
to the column by the fact that it eluted off the column in a low imidazole buffer.   
SDS-PAGE analysis provided more evidence that the protein band observed in 
the SDS-PAGE gel is the targeted protein, M234C HCBR'.  Figure 3.8 shows the results 
of the SDS-PAGE.  Lane 1 is the Fischer EZ Run pre-stained REC protein ladder.  Lane 
2 is the M234C HCBR 1' sample, Lane 3 is the NHCBR' sample.  The banding pattern of 
the native and the mutant are similar.  They both have a major band slightly above the 33 
kD ladder band.  They both show the same minor bands occurring about 24 kD and 22 
kD.  The estimated molecular weight of the mutant is 33.64 kD.  The gel reflects that the 
major band for the mutant is in this region. 
 
Figure 3.8: SDS-PAGE Gel of M234C and NHCBR'  
 
 
Above is an SDS-PAGE gel of the M234C and the native HCBR 1'.  Lane 1: Fischer EZ Run Prestained 
REC protein ladder.  Lane 2:M234C HCBR 1' and Lane 3: NHCBR'.  The bands appear in the 33kD region 
as expected. 
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Table 3.4: Sequencing Results of the Mutated HCBR 1' Plasmids 
 
 
Plasmid name Colony Number Sequence Correct for Mutation 
A234,E244 HCBR' 1 Yes 
A234,E244 HCBR' 2 Yes 
A234,E244 HCBR' 3 Yes 
      
C234, E244 HCBR' 1 Yes 
C234, E244 HCBR' 2 Yes 
C234, E244 HCBR' 4 Yes 
      
S141, E244 HCBR' 2 Yes 
S234, E244 HCBR' 1 Yes 
S234, E244 HCBR' 2 Yes 
S234, E244 HCBR' 3 Yes 
S234, E244 HCBR' 4 Yes 
      
Trp234, E244 HCBR' 1 Yes 
Trp234, E244 HCBR' 2 Yes 
Trp234, E244 HCBR' 3 Yes 
Trp234, E244 HCBR' 4 Yes 
      
A141,E244 HCBR' 1 Yes 
A141,E244 HCBR' 3 Yes 
A141,E244 HCBR' 4 Yes 
      
C141,E244 HCBR' 1 Yes 
C141,E244 HCBR' 2 Yes 
C141,E244 HCBR' 3 Yes 
C141,E244 HCBR' 4 Yes 
      
Trp141, E244 HCBR' 1 Yes 
Trp141, E244 HCBR' 2 Yes 
Trp141, E244 HCBR' 3 Yes 
Trp141, E244 HCBR' 4 Yes 
Plasmids were sequenced to identify that the correct mutation was present in the plasmid.  The gene was 
also analyzed to confirm that no other unintended mutations had occurred. 
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Characterization of M234C HCBR 1' Protein 
Activity Studies 
 Menadione Activity Study 
 The M234C HCBR 1' enzyme was first assayed with the standard enzyme assay 
that has been previously established.49  The 234 mutant did not display any measurable 
activity with the standard assay protocols with assay times up to 10 minutes.   
 The assay was then modified by varying the concentration of menadione from 25 
µM to 180 µM.  This lower range of menadione concentrations was selected to control 
for possible substrate inhibition.  Even after 20 minutes, no measurable enzyme activity 
was detected. 
 NADPH Activity Study 
 A wide range of NADPH concentrations were also explored in order to test 
possible problems with the binding of coenzyme NADPH.  The NADPH concentration 
was increased from the standard assay to see if there is any activity with the M234C 
HCBR 1'.  The NADPH concentration ranged from 300 µM to 500 µM.  Again, no 
measurable activity was recorded from the mutant. 
 Anthracycline Activity Studies 
 An assay was done with both doxorubicin and daunorubicin.  The assays were 
done under standard assay conditions and 300 µM anthracycline in place of menadione.  
Also NADPH concentrations were increased from 50 µM to 150 µM.  As with all other 
attempts, no activity was recorded with this mutant. 
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DTT Activity Study 
 An assay was done with the compound dithiothreitol (DTT) was used to assay any 
disulfide bonds that may have been formed due to the addition of the Cys 234 mutation.  
It is not believed that HCBR has any naturally occurring disulfide bonds and so DTT is 
not hypothesized to interfere with the activity of the protein.  There was no activity 
observable with pre-incubation of the enzyme with DTT. 
Fluorimetry Studies 
NADPH Fluorimetry 
 As with the native His-tagged construct, the coenzyme and substrate binding 
properties of the Cys 234 mutant enzyme were investigated using fluorimetry.  Figure 3.9 
shows the fluorescence quenching as the NADPH is added.  From this data a Kd was 
estimated to be 26.83 µM (Table 3.2).   
 A previously reported Kd for a variant of HCBR1, also with a histidine tag, was 
6.3 ± 0.6µM for CBR1 V88 and 3.8 ± 0.5µM for CBR1 I88 (Covarrubias et. al. 2007).  
These researchers added a 6x His-tag to the N-terminus of the HCBR1 protein by 
inserting the gene into a pET28 vector.  This vector adds the His-tag to the N-terminus of 
the enzyme and also adds between 10-24 extra amino acids.   
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Figure 3.9: Fluorescence of M234C HCBR 1' and NADPH Coenzyme 
 
Coenzyme binding ability was expolored with fluorescence quenching studies.   A 4µM M234C HCBR' 
solution was made and a 1mM solution of NADPH  was added in 1µL increments.  The fluorescence 
values were recorded and graphed. As the active site Trp 229 is quenched a decrease in fluorescence is 
observed. 
 
The Kd values reported in the Gonzalez-Covarrubias are smaller Kd values than 
the Kd values that were observed in this study (Table 3.2).  This smaller Kd value may 
indicate that the pTricHis2 TOPO His-tag used in this research may have a lower affinity 
for the binding of the coenzyme reflected by the increased Kd values.  Within this 
research the coenzyme Kd values vary for the native and the M234C indicating that there 
is a difference in affinity between these two species (Table 3.2). The Kd values indicate 
that the NADPH coenzyme is binding the M234C HCBR 1' with less affinity than the 
native HCBR1' enzyme.  This may indicate a disruption in the coenzyme binding site and 
it is hypothesized that this interruption is due to the polyhistidine tag, although the 
mechanism for this disruption has not been worked out yet.  This data about the binding 
of NADPH to the mutated enzyme further supports the diminished kinetic activity 
observed in the NHCBR 1' enzyme.  There is evidence to support the hypothesis that the 
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polyhistidine tag added to both of these enzymes is interfering with the binding of the 
cofactor. 
NADP+ Fluorimetry 
 Fluorimetry studies with the molecule NADP+ and HCBR 1 have been completed 
in this lab before; however, the information has not been published. NADP+  is a product 
for the enzyme re-dox reaction and shares close structure with NADPH, varying only by 
a hydrogen and charge.  It is preferred to complete fluorescence quenching studies with 
NADP+ because it does not fluoresce in the same region as HCBR 1.  It is expected that 
HCBR 1 enzyme will bind the NADP+ with similar affinity as the NADPH molecule.  It 
is expected that binding of the NADP+ will lead to quenching of the enzyme fluorescence 
(Figure 3.10). 
The NADP+ fluorescence quenching data suggests that the HCBR 1' is binding the 
NADP+ molecule with a higher affinity than it binds the NADPH molecule (Table 3.2).    
 
Figure 3.10: Fluorescence of M234C HCBR 1' and NADP+ 
 
Coenzyme binding ability was expolored with fluorescence quenching studies.   A 4µM M234C HCBR' 
solution was made and a 1mM solution of NADP+ was added in 1µL increments.  The fluorescence values 
were recorded and graphed.  NADP+ is preferred in fluorescence studies because it does not fluoresce in the 
same region as the protein.  As the active site Trp 229 is  quenched a decrease in fluorescence is seen. 
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Anthracycline Binding by Mutant HCBR 
 
 An intrinsic protein fluorescence quenching assay was done with the 
anthracyclines daunorubicin and doxorubicin. Both effectively quench the protein 
fluorescence (Figures 3.11 and 3.12).  Kd values were found to be 35.8 µM and 31.5 µM 
for doxorubicin and daunorubicin, respectively (Table 3.2).    
 
 
 
Figure 3.11: Fluorescence of M234C HCBR 1' and Daunorubicin 
 
Substrate binding ability was expolored with fluorescence quenching studies.   A 4µM M234C HCBR' 
solution was made and a 1.24mM solution of daunorubicin was added in 1µL increments.  The 
fluorescence values were recorded and graphed.  As the active site Trp 229 is quenched a decrease in 
fluorescence is observed. 
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Figure 3.12: Fluorescence of M234C HCBR 1' and Doxorubicin 
 
Substrate binding ability was expolored with fluorescence quenching studies.   A 4µM M234C HCBR' 
solution was made and a 1mM solution of doxorubicin was added in 1µL increments.  The fluorescence 
values were recorded and graphed.  As the active site Trp 229 is quenched a decrease in fluorescence is 
observed. 
 
  
 There is no previously published data from which a comparison can be made 
regarding these Kd values.  The decrease in fluorescence as the substrate was added is 
good evidence that the substrates are able to bind the mutant.  The Kd values can be 
deceiving; however, because this study doesn’t insure that optimal binding for catalysis 
has occurred in the active site.  A substrate can bind without optimal position for catalytic 
reactions to occur but still induce fluorescence.  Based on comparison to the 
anthracycline Kd values obtained for the native HCBR', there may be a modest decrease 
in anthracycline binding affinity when methionine 234 is mutated to cysteine. The results 
from these experiments do not support the hypothesis to specific aim 3.  It was 
hypothesized that the M234C HCBR 1' would allow more room in the active site for the 
  68 
substrate doxorubicin to bind.  However, Kd values in this study do not show a significant 
difference between the two anthracycline substrates. 
Circular Dichroism of Native HCBR' and M234C HCBR 1' 
 The circular dichroism technique was used to assess any difference in secondary 
structure between the NHCBR' and the M234C HCBR' enzyme.  These enzymes are the 
same with the exception that the mutant has a cysteine amino acid at position 234.  This 
experiment was trying to confirm that the mutated enzyme was folded correctly.  It was 
found that there was no significant difference in secondary structure between the two 
enzymes (Figure 3.13).  
 
Figure 3.13: Circular Dichrosim of Native and M234C HCBR 1' 
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It was found that there was no significant difference in secondary structure between native and M234C 
HCBR 1'. 
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This may be evidence that the mutated enzyme is folded correctly in reference to the 
NHCBR' enzyme.  This is evidence that the lack of activity that is seen in the mutant 
compared to the native may be indicative that amino acid 234 has an important role in 
docking substrates in the active site.  It has been observed that when the methionine 234 
is mutated to a cysteine that there is no observable activity in the mutant.   
Conclusion for Results 
 The results of these studies indicate that the NCHBR 1' enzyme does not behave 
the same as the previously published HCBR1 enzyme.49  This histidine modified enzyme; 
however, still shows activity with the known substrate menadione and NADPH, even 
though the binding of the NADPH molecule may be somewhat perturbed.  The M234C 
HCBR' enzyme also has been affected by the addition of the histidine tag; however, when 
compared to the native enzyme with histidine tag the mutant does not show any 
observable activity.  This difference in kinetic behavior between these two histidine 
tagged enzymes is important and may be preliminary evidence that suggests that position 
234 in the HCBR 1 enzyme is an important amino acid that helps control substrate 
binding in the enzyme active site.   
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CHAPTER 4 
DISCUSSION 
DESIGNING A POOR ANTRHACYCLINE SUBSTRATE FOR HUMAN 
CARBONYL REDUCTASE 1 
Application of the Structure-Based Drug Design for HCBR 1 
Structure based drug designs give researchers an information guided approach to 
the study of their biological target, quite often times a protein.  Bioinformatics servers 
store large amount of data about a protein that many separate researchers are studying.  
Structural information can be used to categorize the protein into a protein family.  Protein 
families and superfamilies are composed of proteins that have a high degree of similarity 
due to conserved regions and domains found within the protein.   Once a protein has been 
put into a family insights can many times be gained about the structure/function 
relationships of the protein based on the highly conserved regions and the corresponding 
functions in other members of that family.70   
SDR Superfamily Characteristics 
 HCBR 1 (E.C. 1.1.1.184) is a member of the SDR superfamily of proteins which 
consists of over 3000 members.  The SDR family is ubiquitous, occurring in both 
prokaryotic and eukaryotic organisms.  They have a role in the metabolism of a wide 
range of biological compounds including alcohols, sugars, aromatic hydrocarbons, 
steroids, and prostaglandins.  All SDR proteins share conserved primary structural 
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elements that indicate common fold, active site, reaction mechanism, and co-
substrate/substrate binding regions.  The general structure is a cofactor-binding region in 
the N-terminus, catalytic active site in the central portion and a substrate binding region 
of the C-terminus.  Those members that are oligimers have a C-terminal extension that 
allows for binding subunits.  The C-terminal region of the SDRs has the greatest 
variability.71 
 The catalytic residues of SDRs are found in a region comprised of a conserved 
Tyr-x-x-x-Lys region.  The Tyr residue exists in an ionized form which is stabilized by 
the side chain of the Lys (Figure 4.1).  The positive charge of the Lys attracts the oxygen 
of the carbonyl substrate establishing a partial positive charge on the carbon and a partial 
negative charge on the oxygen.  This allows for a nucleophillic attack from the hydride of 
the NADPH nicotinamide ring.72   
Figure 4.1 Nucleophillic Attack of the Substrate 
 
 
 
The active site of SDR proteins have a conserved Tyr-x-x-x-Lys residues.  The sidechain of the Lys residue 
stabilizes the ionized form of the Tyr residue.  The oxygen of the carbonyl group is attracted to the Tyr 
residue creating a slightly negative charge on the oxygen.  This leaves a partial positive charge on the 
carbon.  The H atom of the NADPH initiates a nucleophillic attack on the carbonyl group and a proton is 
donated from the Tyr residue.  72 
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Analyzing the HCBR 1 Crystallized Structure  
The RCSB Protein Databank has a x-ray crystal structure of HCBR 1 submitted 
by Tanaka et.al.67  This structure is important to the research discussed in this thesis 
because it has both a bound inhibitor molecule and the bound coenzyme, NADPH.  This 
information confirms the active site for both the cofactor NADPH and the active site for 
the substrate.  Examination of this active site structure of HCBR 1 has lead to the 
identification of what are believed to be the catalytic amino acids.   
The HCBR 1 enzyme catalyzes the transfer of the pro-4S-hydrogen atom of the 
nicotinamide ring of NADPH to the carbonyl carbon of the substrate.59  In the literature a 
catalytic triad of amino acids have been described, namely Tyr 193, Ser 139, and Lys 
197.56,67,73  This region is a homologous region that has been found throughout the 
carbonyl reductase families.  The role of these enzymes is to facilitate the movement of a 
proton from the hypothesized proton donor, Tyr 193, to the oxygen of the substrate 
carbonyl through a hydrogen bonding network (Figure 4.2).   
 
Figure 4.2: Daunorubicin Reduction by HCBR 1 
  
 
HCBR 1 catalyzes the reduction of anthracyclines at the C-13 carbonyl.  A hydride is transferred from the 
Pro-4S-H atom of the NADPH nicotinamide ring.  The hydride acts as a nucleophile that attacks the 
slightly positive C-13 carbonyl.  This pushes electrons from the double bond to the oxygen.  The oxygen 
accepts a proton from the Tyr 193 amino acid in the HCBR 1 active site.   
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Analysis of the Active Site of HCBR 1 
 The x-ray crystal structure of HCBR was used in the computer program Wincoot 
to dock the known substrate doxorubicin and daunorubicin.  Using the bound inhibitor as 
a model the C-13 carbonyl that is known to undergo reduction by HCBR 1 was aligned in 
the correct position.  The research conducted by Slupe et.al.49 has established that the C-
13 carbonyl of anthracyclines is the preferred substrate over that of the quinone carbonyls 
for HCBR 1.  Examinations of the interaction of the anthracyclines and amino acids in 
the active site led to the identification of Met 234, Met 141 and Trp 229 as potential 
amino acids that play a significant role in recognizing and docking substrates in the active 
site.  This analysis has also led to the hypothesis that site 234 selects substrates due to 
steric interference.  It was noted that the anthracycline daunorubicin is a better substrate 
for this enzyme than doxorubicin represented by its higher catalytic efficiency value.49  
The only difference in these molecules is that daunorubicin lacks the alcohol group 
attached to C-13 side chain observed in the doxorubicin molecule.  This difference in 
structure has led to the postulation that the alcohol group on the C-13 side chain of 
doxorubicin interferes with Met 234 and disrupts optimal binding for catalysis. It is 
hypothesized that this interaction leads to the lowered catalytic efficiency as compared to 
that for daunorubicin.  This research project used site-directed mutagenesis procedures to 
mutate the amino acids to those with a smaller side chain to test the steric hindrance 
hypothesis.  The research examining the changes in enzyme behavior due to the site-
directed mutagenesis is still ongoing.  
 Recently Carlquist and coworkers undertook a computational chemistry 
experiment where they used the computer program ArgusLab 4.0.1 to dock known 
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flavonoid inhibitors into the active site of HCBR 1.74  Their results also suggest that Met 
234 and Trp 229 may play a significant role in binding substrates/inhibitors in the active 
site.  Unlike our hypothesis, they suggest that these amino acids participate in chemical 
interactions with the substrates by anchoring the substrate with hydrogen bonds.  They 
postulate that the Trp 229 residue participates in aromatic-aromatic interactions to 
increase affinity with the substrates.74  Their recognition of these two amino acids as 
being important to substrate-enzyme interactions agrees with our hypothesis that these 
amino acids play a significant role in substrate binding.  We do disagree with the 
mechanism that these amino acids use to interact with the substrate – especially the Met 
234 site.   
Receptor-Based Drug Design Cycle 
 The receptor-based drug design cycle focuses on small, nonprotein ligands.  A 3-
D structure of a protein-ligand complex is used as the basis for the rational design of a 
new ligand.  The information that is gathered is then used to synthesize a new drug 
candidate with features that are believed to be beneficial. To test a hypothesis about the 
new drug design site-directed mutagenesis of the enzyme is often used and data about the 
enzyme-ligand interaction is collected.75   
 The research of HCBR 1 is also utilizing a receptor-based drug design.  The 
literature states that HCBR 1 is known to be a promiscuous enzyme having a large range 
of unrelated substrates in the laboratory.  Although a lot of substrates have been 
identified in the laboratory setting the physiological role and the actual physiological 
substrates have yet to be identified.   
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  In this project we are aiming to learn about the chemical interactions that occur 
between the anthracyclines and HCBR 1.  Concerning the Met 234 site we believe that 
this amino acid sterically hinders the binding of doxorubicin due to the extra alcohol 
group on the C-13 side chain leading to a lower catalytic efficiency compared to 
daunorubicin.  The end result is the hope that a new anthracycline drug analog can be 
designed that changes the C-13 side chain perhaps by adding a bulky residue.   
 Designing analogs of anthracyclines is not new.  Over 2000 anthracyclines have 
undergone similar modifications.1  The goal of all of these analogs was to reduce the 
cardiotoxic side effects that are observed in anthracycline treatment.2  Researchers have 
added large chemical groups to different parts of the drug such as the amino group, the 
sugar moiety or the aglycone group.2  The hope was that the anthracycline derivatives 
would have a lower cardiotoxic side effect but have the same or improved cytotoxic 
properties.1  Data has shown that these derivatives have not always changed the 
cardiotoxic properties, on an equivalent drug dosage, and in many cases have 
significantly decreased the cytoxic properties of the anthracycline.     
 We hope that our approach will result in a different outcome for our designed 
anthracycline derivative.  The C-13 side chain is one region that has not been altered in 
the other derivatives.  We believe that our rational drug design has given substantial 
support for the changing of the C-13 side chain.  If the future kinetic data supports our 
hypothesis, we would consider adding a bulky group to the C-13 side chain to prevent the 
binding of the anthracycline in the active site of HCBR 1.  This in turn would prevent the 
metabolism of anthracyclines by HCBR 1.  We believe that this analog would directly 
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address the issue of cardiotoxicity because data suggest that C-13 metabolism is a major 
driving force in the cardiotoxic side effects seen in anthracycline treatment.             
Design of Ineffective Substrate 
 The goal of this research project is to collect information about the mechanism of 
HCBR 1 anthracycline specificity so that a new anthracycline analog can be designed.  
The goal is that the new analog is an ineffective substrate for HCBR 1.  The result will be 
a new anthracycline analog that no longer fits into the active site and resists metabolism 
to an alcohol product.  The challenge is designing an anthracycline that maintains its 
cytotoxic behavior and reduces or eliminates its cardiotoxic side effects. 
 Research shows that there is significant evidence that the HCBR 1 enzyme has a 
significant role in metabolizing anthracyclines to an alcohol product in the cell.  There is 
significant evidence that this alcohol product is a significant cause of the cardiotoxicity 
observed in the heart tissue of some patients.  This research suggests that the C-13 side 
chain has an important role in the binding of the anthracycline to the HCBR 1 enzyme 
and modifications to the anthracyclines C-13 should be explored with the end goal of 
creating an ineffective substrate for HCBR 1. 
Analyses of the Activity of M234C HCBR 1' 
Mutating Site 234 to Cysteine Yields No Discernable Activity to Date 
 To explore the relationship of the Met 234 and its interactions with substrates the 
HCBR 1 enzyme was successfully mutated to Cys 234, Ala 234, Ser 234 and Trp 234.  
To date only the activity of M234C has been addressed.  Research is ongoing to explore 
the activity changes of the Ala 234, Ser 234 and Trp 234. 
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 The pTrcHis2 TOPO system was used to add the histidine tag to the end of the 
HCBR 1 gene.  The histidine tag was successfully added to the C-terminus of the protein.  
This kit also adds two extra amino acids to the N-terminus and 23 extra amino acids 
before the six histidines on the C-terminus end of the protein.  The extra 23 amino acids 
are epitopes that are used to bind antibodies for western blot procedures.  There is more 
than one way to attach a histidine tag to the end of a protein including vectors like the 
pTrcHis TOPO as well as conventional PCR reactions.  Addition of a histidine tag by 
PCR utilizes primers designed with a histidine overhang.  As the gene is amplified the 
histidine tag is incorporated into the gene.  The pTrcHis TOPO kit was chosen because it 
has been used in a neighboring lab without significant impacts on the expression of the 
protein.               
 Possible Complications Inhibiting M234C Activity 
 During the course of this research it was found that the histidine tag added by the 
vector may be interfering with the activity of the NHCBR.  It has been found that 
choosing to use the pTrcHis2 TOPO vector system has proved to have some inherent 
problems for this enzyme.  Our data shows evidence that the histidine tag got in the way 
of catalysis by interrupting the binding of the NADPH cofactor.  This discovery 
complicates the analysis of results seen for the 234 mutations. 
 Several of the results suggest that the M234C mutation does not have activity that 
can be measured by the techniques used in this laboratory.  The His-tagged native HCBR 
protein, even though activity was decreased due to the histidine tag, did show a 
measurable amount of activity.  It remains possible that if other more sensitive techniques 
such as fluorimetry for measuring enzyme activity were used, perhaps activity for 
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M234C could be measured.  It is worth noting that M234C is the only 234 mutant that 
was fully characterized.  There is preliminary data to suggest that the Ala 234 mutation 
also appears to lack activity; however, more studies need to be done to support this claim.   
 If the result that the M234C HCBR' has no activity holds true then the following 
may be concluded.  One possibility is that the Met 234 makes an important interaction in 
positioning compounds in the active site as previously suggested.74  If so, our hypothesis 
that Met 234 acts to restrict the size of substrate that can productively bind in the active 
site through sterics is not correct.  Another possibility is that Met 234 assists in coenzyme 
binding in some way and its role is essential to the catalytic activity of the enzyme.  This 
option is supported in part by our fluorescence quenching studies.  And yet another 
plausible explanation is that Met 234 is required for the structural integrity of the active 
site and that changing it to cysteine disrupted this structure, thereby rendering the enzyme 
inactive.  More work needs to be done in order to resolve this problem.   
 M234C May Display Substrate Binding Ability 
After the realization that the histidine tag interfered with the native HCBR 1' 
expression fluorimetry studies were done to try and assess the ability of the NADPH and 
NADP+ cofactor binding and substrate binding independent of each other.  Kd values, a 
rate constant that represents the dissociation of substrates from enzymes, were generated 
from the data collected.  A smaller Kd value indicates a greater affinity for that substrate. 
Due to the fact that the environment of the coenzyme binding pocket and the 
substrate binding pocket are different Kd values cannot be directly compared between 
these two different active sites in the enzyme.  However, the experiments are trying to 
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assess the ability of both the native and M234C HCBR' enzyme to bind these substrates 
independently.   
 In the native HCBR' NADP+ has twice the affinity than the NADPH molecule.  
We were expecting that NADP+ and NADPH would bind the enzyme with similar 
affinity.  We choose to use both the NADPH and NADP+ because NADPH fluoresces in 
the same region as the HCBR 1 enzyme, whereas NADP+ does not fluoresce in the same 
region.  NADP+ only differs from NADPH by one hydrogen and it possesses a positive 
charge on the nicotinamide ring.  It is known that the NADP+ is able to bind the HCBR 1 
enzyme lacking the histidine tag.  The fact that we see a difference in affinity between 
these two coenzymes in the HCBR' is surprising and may indicate that this form of 
enzyme is not binding the coenzyme as efficiently as HCBR.  The results do show that 
the HCBR' is not completely unable to bind the coenzyme.  This information coupled to 
the fact that the HCBR' has decreased activity may indicate that the coenzyme binding 
site has been interrupted by the addition of the histidine tag.   
 The M234C HCBR' was expected to have the same Kd values for the coenzymes.  
The mutations that are introduced at the 234 site are not hypothesized to affect the 
binding site of the coenzyme.  M234C did not have as large of a difference between the 
affinities of NADPH and NADP+; however, there was a difference between the Kd 
values.  These may indicate that the M234C has different affinities for the two different 
coenzymes.   
The native enzyme displayed more affinity for both the coenzymes as compared 
to the M234C.  Considering the NADPH data the native HCBR' has twice the affinity 
than the mutant.  For NADP+ the native has four times the affinity than the mutant. 
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The hypothesis for this series of fluorimetry studies was that the native and 
M234C HCBR' enzymes would bind the coenzyme in the same or very similar manner.  
These data results raise the question as to why the native has more affinity for both 
coenzymes than the mutant.  Both of these enzymes are in the same histidine tag system 
and are hypothesized to be affected by the histidine tag in the same manner; however, 
they clearly show a difference in the ability to bind coenzymes.  This data may suggest 
that the M234C has some perturbation in the coenzyme active site leading to a decrease 
in binding ability of the coenzymes.  More studies will need to be done to substantiate 
any changes in the mutant coenzyme site. 
The coenzyme site is located near the N-terminus region of the protein and the 
histidine tag was added to the C-terminus of the protein.  It was not assumed that the 
histidine tag would affect the coenzyme site in any way; however, I believe that there is 
evidence that the histidine tag is interfering with the active site in some way.  Any 
changes that may have occurred in the coenzyme binding site have not been defined as of 
yet.  The mechanism of the interference that the histidine tag may or may not have with 
the coenzyme site has not been defined as of now. 
The ability of the native and mutant HCBR' enzymes ability to bind anthracycline 
substrates were also investigated.  In the native HCBR' daunorubicin and doxorubicin 
have about the same affinities for the active site.  Although it is important to consider that 
the doxorubicin error on this data is larger than the NADP+ data.  Steady state kinetics 
concerning the HCBR enzyme and anthracyclines indicate that daunorubicin is a better 
catalytic substrate than doxorubicin reflected by a larger catalytic efficiency value.  Due 
to this information, I was expecting that daunorubicin would have a higher affinity for the 
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substrate active site than doxorubicin; however, the fluorimetry data does not support this 
idea.   
The M234C enzyme has a similar trend concerning the affinities of the two 
anthracycline substrates.  Daunorubicin and doxorubicin have essentially the same Kd 
value; although, daunorubicin has a slightly increased affinity.  In this data the error 
values are very comparable as well.  Unlike the native HCBR', activity studies of M234C 
indicate that the substrates are not undergoing a re-dox reaction.  The fluorimetry data 
indicates that the mutant is able to bind anthracyclines although the binding may occur in 
a manner that does not facilitate catalysis reactions.  These results may indicate that the 
catalytic machinery has been interrupted in some way in this enzyme.  Further study and 
analysis will need to be done to understand what changes have occurred in the substrate 
active site of the mutant enzyme.     
Comparing between the native and mutant form, the native has slightly more 
affinity for both daunorubicin and doxorubicin.  The difference is not as great as 
compared to the coenzyme data between the two forms of enzyme.  Suggesting that the 
binding ability of the two forms of enzymes are similar; however, steady state kinetics 
indicate that activity varies greatly.  Investigation of Met 234’s role in the catalysis 
reaction is warranted to understand the difference seen in catalysis but perhaps not in 
binding ability of substrates between native and mutant.   
The doxorubicin data is very important to this study because our hypothesis was 
that we would see a greater ability for the doxorubicin to bind the M234C mutant and 
thus see an increased catalytic efficiency.  The fluorimetry data does not support this 
hypothesis.  The native has increased affinity for the doxorubicin molecule compared to 
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the M234C mutant.  Both the steady state kinetic data and the fluorimetry data disagree 
with the stated hypothesis for specific aim 3.  These results raise questions as to the role 
of Met 234 in the binding of substrates.  Perhaps this interaction involves more than just a 
steric hindrance in the active site.   
Overall, concerning the fluorimetry data the native HCBR' enzyme has more 
affinity for all four molecules used compared to the M234C form.  All of the results were 
surprising and unexpected.  The coenzyme data indicate that the histidine tag is 
interfering with the binding of substrates and the substrate data indicate that the M234C 
is not able to bind doxorubicin with greater affinity.       
 Circular dichroism studies were done to try and assess the folding ability of both 
the NCHBR' and M234C HCBR' enzymes.  The folding of the enzyme was also trying to 
get at the question as to why the catalysis machinery has been interrupted.  If the mutant 
enzyme is not folded correctly this could interrupt the catalysis ability of the enzyme.  
These experiments suggest that there is no difference in secondary structure between the 
native and the M234C HCBR' enzymes.  Providing preliminary evidence that M234C 
HCBR' may be folded correctly but lacking catalytic activity with the menadione 
substrate.  
 Conclusion 
It is difficult to assess the activity of the M234C due to the interruption posed by 
the histidine tag.  The ideal situation would be to compare the data collected on the 
M234C HCBR' mutation to the published literature for the pET5a HCBR enzyme; 
however, due to the histidine tag complications it is not possible to do this comparison.  
Even though the chosen expression system is not an ideal system it is possible to compare 
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the data from the NCHBR' to the M234C HCBR' within reason.  It is clear that the 
histidine tag is interfering with the binding of the NADPH cofactor; however, it is still 
possible to measure activity for the NHCBR'.  The M234C mutation can be assumed to 
have the similar problems with the histidine tag interfering with NADPH binding.  Unlike 
the NHCBR' the M234C does not have any measurable activity.  This data lends some 
support and evidence that the 234 mutations have interrupted the catalysis ability of the 
HCBR 1' enzyme.  Further study and analysis will need to be done to determine what 
roles the 234 position plays in the catalysis reaction.   
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CHAPTER 5 
FUTURE WORK 
IMPROVING THE HIS-TAGGED EXPRESSION SYSTEM FOR HCBR 
Reducing the Histidine Tag 
 Several lines of evidence suggest that the pTrcHis2 TOPO system is not a good 
expression system for this protein.  The result of this expression vector was a native 
protein that did not have the comparable kinetic behavior as that previously published.49  
The fact that the histidine tagged protein eluted off in a low imidazole concentration 
buffer may also suggest a weak binding of this histidine tag to the nickel resin, perhaps 
because of interaction with the remaining protein, thus obscuring the availability of the 
histidines to bind to the nickel resin.  Overall the character of the protein is compromised 
and a new expression system must be explored. 
Current research is ongoing to delete the extra DNA bases that code for the extra 
23 amino acids that were added with the pTrcHis2 TOPO vector.  There are two 
techniques that are being used to try and reverse this condition. 
One technique utilizes the Phusion site-directed mutagenesis kit.  With this kit 
primers are designed that flank the region that is to be deleted.  One primer starts on the 
leading strand at the first histidine and extends the plasmid.  The second primer binds the 
lagging DNA strand at the end of the HCBR 1 gene and the primer extends the plasmid.  
The result is that the region in the middle of the HCBR 1 gene and the His-tag (the 
aforementioned 23 added amino acid residues) is removed.  
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Another procedure that is being explored is to design a primer with a histidine 
overhang that is directly attached to the C-terminus of the HCBR gene.  The overhang 
will be incorporated into the HCBR 1 gene and the result is that the gene is amplified and 
the histidine tag is added to the end of the gene.  The amplified gene will then be inserted 
back into the pTrcHis2 TOPO expression vector.   
If either one of these techniques work the six histidine tag will be added directly 
to the end of the gene.  Our computer modeling techniques show that the last amino acid 
in the protein is on the surface of the HCBR 1 enzyme which is the desired position when 
adding a histidine tag.  We believe that if the histidine tag can be successfully added to 
the last amino acid that the histidine tag will be on the surface of the protein and will be 
available to bind to the nickel resin.  It seems likely that we will see an increased affinity 
for the histidine tagged HCBR 1 to the Ni++ resin and we will observe that an increased 
concentration of imidazole will be needed to elute off the protein.  
When these experiments are complete we will be looking for several key changes 
in the native HCBR 1 protein with histidine tag.  First we will be looking to see if the 
histidine tag binds to the nickel resin with a higher affinity.  We expect the protein to 
require higher concentrations of imidazole for elution from the nickel resin because to 
date these proteins have been eluting off in a very weak concentration of imidazole.  If 
the concentration of imidazole needed to elute the protein increases this will indicate a 
better binding of the protein to the nickel resin.   
Next, kinetic assays will need to be done to fully assess the behavior of the newly 
constructed variant of the His-tagged HCBR 1 protein.  In order to move forward, the 
kinetic behavior of the native must be the same or very similar to the published values for 
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HCBR kinetics.  If this expression system results in restoring the kinetic behavior than 
this expression system will be a better expression system than the current pTrcHis2 
TOPO system.   
Assess the Activity of Mutated 234 HCBR 1 
 Once a protocol is established that will remove the extra amino acid residues 
added by the initial histidine tag then this procedure will be used to remove the extra 
bases from the Cys 234, Ala 234, Ser 234 and Trp 234 genes. 
 The proteins will be expressed in the established purification protocol.  Steady 
state kinetics studies will be done to establish if there is or is not activity with these 
mutations.  If there is observable activity than a kcat, Km and kcat/Km values will be 
determined for menadione, daunorubicin, and doxorubicin. 
 In the event that these mutations continue to lack activity than further experiments 
will need to be done to establish the condition of the proteins.  One such experiment 
could include crystallization of the enzyme with a known substrate.  This would give the 
researcher an ability to look at a 3-D representation of the enzyme and see if there are 
changes in the position of the substrate and the new interaction of the 234 side chain.   
Met 141 and Trp 229 Mutated HCBR 1 
 It is hypothesized that three amino acids work in tandem to guide and dock 
substrates in the active site.  These three amino acids are Met 234, Met 141 and Trp 229.  
Met 234 has been discussed extensively in this paper; however, it is important to mention 
the hypothesized role of Met 141 and Trp 229.  They are also believed to restrict 
substrate binding in the binding pocket via steric hindrance although this mechanism has 
not been as clearly defined as the proposed mechanism of Met 234.  The Met 141 and Trp 
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229 amino acids are observed surrounding the aglycone ring structure of both 
daunorubicin and doxorubicin in our computer based models.  It is hypothesized that 
mutation of these amino acids, individually and in tandem, to amino acids with smaller 
side chains such as Cys, Ser or Ala that an effect on the catalytic efficiencies with known 
substrates will be observed.    
Ongoing research indicates that the Met 141 mutants have activity with the known 
substrate menadione, unlike the M234C HCBR' enzyme.  The 141 mutant enzymes are 
currently in the same histidine tag system as previously mentioned.  This limits the ability 
to define steady state kinetic values as for 141 mutations as of now.   Future experiments 
will involve making these mutations in an enzyme construct whereby a histidine tag does 
not interfere with enzyme activity.  This system may include adding the histidine tag 
directly to the end of the enzyme in the same manner as the M234C.  Another option is to 
remove the histidine tag completely from these specific mutations.  Due to the fact that 
these mutations currently show activity it may be possible to purify these mutants using 
the standard anion exchange purification procedure outlined by Slupe et. al.49  In this 
system the data could be directly compared to the published HCBR pET5a steady state 
kinetic values leading to the ability to define the changes that have occurred in these 
mutations. 
Conclusion: Information is the Beginning of Drug Design 
The results that are generated from the analyses of 234, 141 and 229 mutations will guide 
our understanding of the substrate-enzyme interactions in the active site.  This 
information is crucial to the rational drug design approach that this laboratory has 
undertaken to design a new anthracycline analog.  We believe that the information will 
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allow a unique design to the anthracycline that will lead to lowered cardiotoxic risk 
because the anthracycline analog will resist metabolism by HCBR 1.   
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